









The Prevalence of Hearing Loss in HIV-infected South African Adolescents 
on Antiretroviral Therapy 
AGATHA TAFADZWA BANGA
BNGAGA001
Dissertation submitted in partial fulfilment of the requirements for the degree
MASTER OF PUBLIC HEALTH
in Epidemiology
in the  
School of Public Health and Family Medicine 
Supervisor: Professor Landon Myer, School of Public Health and Family Medicine, 
University of Cape Town 
13 March 2017
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
Published by the University of Cape Town (UCT) in terms 












To my grandfather, Peter Doice Tayengwa Banga, 
in memorium;  ab ove maiori discit arare minor. 
ii 
Declaration 
I, Agatha Banga (BNGAGA001), hereby declare that the work on which this 
dissertation/thesis is based is my original work (except where acknowledgements indicate 
otherwise) and that neither the whole work nor any part of it has been, is being, or is to be 
submitted for another degree in this or any other university.  
I empower the university to reproduce for the purpose of research either the whole or any 
portion of the contents in any manner whatsoever. 
Signed: 








This mini-dissertation is presented in four parts. Part A (‘Protocol’) provides a background 
and justification for the study, as well as describing the methodology of the cross-sectional 
analysis. Part B (‘Literature Review’) illustrates and summarises literature relevant to the 
objective of the cross-sectional analysis. Part C (the journal-ready ‘Manuscript’) presents the 
methodology, findings and discussion based on the cross-sectional analysis. Part D 




The use of Antiretroviral Therapy (ART) has increased longevity amongst HIV-infected 
populations. As a result, children perinatally infected with HIV (PHIV+) are living into 
adolescence for the first time in the history of the global HIV epidemic. PHIV+ adolescents 
are a unique population as they bear the combined effects of chronic HIV-infection and the 
prolonged use of ART. Sub-Saharan Africa continues to make a significant contribution to 
the global HIV burden, and concurrently has one of the highest prevalences of hearing loss in 
the world. Although it is known that hearing loss is common among PHIV+ adolescents, 
there remains sparse evidence about predictors for hearing loss in this population, especially 
in the developing world. Research is highlighting the importance and need for further 
investigation into this unique population with inimitable health needs.  
In South Africa, the Cape Town Adolescent Antiretroviral Cohort (CTAAC) - a prospective, 
descriptive cohort study - began in July 2013, looking at 625 adolescents (515 PHIV+ and 
110 HIV-non-infected (HIV-)). The overall objective of the CTAAC was to investigate the 
progression of chronic HIV-infection among PHIV+ adolescents on ART. This dissertation is 
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based on a cross-sectional analysis of audiometric data from the CTAAC participants. The 
objective of this cross-sectional analysis was to investigate hearing loss among PHIV+ 
adolescents on ART, and HIV-adolescents in Cape Town, South Africa.  
Methods 
 
A cross-sectional analysis was carried out to describe the prevalence, nature and predictors 
(demographic, past medical history, clinical findings) of hearing loss in adolescents between 
9 and 14 years of age. Screening pure-tone air-conduction (AC) thresholds above 30 decibels 
(dB) were considered to be indicative of debilitating hearing loss. Statistical analysis included 
univariate analysis and multivariate logistic regression.  
Results 
 
The cross-sectional analysis included data from 540 participants. 225 (52%) were male, with 
a median age of 12 years. A varying degree of hearing impairment was observed in 19% of 
all the adolescents in the study. Multivariate analysis showed the following predictors for any 
hearing loss: an unmarried primary caregiver (odds ratio (OR) 0.59; 95% confidence interval 
(CI), 0.39; 0.91, p = 0.015), being female (OR 1.67; 95% CI, 1.12; 2.51; p = 0.013) and 
reports of being troubled by ear pain or discharge in the last month (OR 2.54; 95% CI, 1.55; 
4.17; p = <0.001) after adjustment. Univariate analysis showed an association between 
hearing loss and a longer duration on ART among PHIV+ adolescents (OR 1.80, 95% CI 
1.17; 2.75, p = 0.007). 
Discussion 
 
Data showed that the prevalence of hearing loss appears to be comparable between PHIV+ 
and HIV- adolescents in Cape Town. In low resource settings, a history of ear pain or 
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discharge within the last month may be used as a screening tool for a hearing assessment, and 
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This protocol represents a study aimed at investigating hearing loss among perinatally HIV-
infected (PHIV+) adolescents on antiretroviral therapy (ART), and HIV-non-infected (HIV-) 
adolescents in Cape Town, South Africa.  
The study consists of a secondary analysis of pure-tone audiometry results, clinical history, 
physical examination findings, HIV-related blood sample results, demographics, health-
related and socio-economic status indicators, collected between July 2013 and February 
2015, during the first visit for participants enrolled in the Cape Town Adolescent 
Antiretroviral Cohort (CTAAC) Study, on a cross-sectional sample of 540 adolescents (432 
with perinatal HIV-infection on ART and 108 HIV-uninfected adolescents). 
South Africa remains a large contributor to the global HIV burden, and is a part of the 
developing world where the burden of hearing loss is highest. ART has increased longevity in 
HIV-infected populations, resulting PHIV+ children living to their adolescence with chronic 
HIV-infection and prolonged use of ART. Various studies have suggested that PHIV+ 
adolescents have higher rates of hearing impairment compared to their HIV- uninfected 
counterparts. Few studies have been done in South Africa including a longitudinal follow-up 
of a cohort as large as the CTAAC Study.  Knowledge about hearing loss in PHIV+ 
adolescents and the specific risk factors is scarce. There is a consensus that research into 
hearing loss seen among PHIV+ adolescents needs to be up-scaled, particularly in low-
resource settings.  
In this study, a cross-sectional analysis will be carried out, descriptive analyses and relevant 
methods for comparing HIV-infected and HIV- adolescents will be instated, and logistic 
regression models will be established to identify predictors for hearing loss in PHIV+ 







There are over 36 million people living with HIV worldwide, of which 19 million live in East 
and Southern Africa (1). South Africa is one of six countries that make up for half of the 
world’s adolescent population living with HIV (2). 
Hearing loss is common amongst children and adolescents who had perinatal exposure to 
HIV. HIV positive children and adolescents show higher rates of hearing loss compared to 
their HIV uninfected counterparts (3). 
According to the World Health Organisation (WHO), hearing thresholds above 30 decibels 
(dB) in the better ear are indicative of disabling hearing loss (4). In children and adolescents, 
hearing is essential to spoken language, academic performance and social engagement (5). 
Therefore, hearing loss becomes an immediate challenge towards social integration and 
education (5). The effect of hearing loss in the long run has a negative impact on various 
aspects of an individual’s life, including attitude, social skills, self-esteem and job 
performance. This in turn can affect the economic and social development of communities 
and the country at large (5).  
The majority of the 360 million people worldwide who live with debilitating hearing loss 
come from low and middle income countries, with children making up to 10% of those 
affected by hearing loss (5). Seventy-five percent of childhood hearing loss is preventable in 
low income countries, with over a third being due to infection (5).  
Some low income countries report levels of hearing loss in HIV-infected children to be 
nearing 40% (6). A systematic review exploring the burden of disability in Sub-Saharan 
Africa  showed a significant increase in hearing impairments amongst those living with HIV, 
with a median prevalence of 24.1% (95% CI: 19.2–29.0% (7)). Another study in an HIV 





Africa, the largest cohort study (231 participants) of diagnostic audiology testing that looked 
at hearing loss in HIV infected children and HIV uninfected but exposed children showed 
significantly higher levels of hearing loss in these populations compared to their healthy 
counterparts (3). In Cape Town, a similar study used a smaller sample, showing a 21.6% 
prevalence of hearing loss amongst HIV infected children. Despite this figure not being 
statistically significantly different to that of hearing loss amongst uninfected children, the 
study pointed to a higher level of hearing sensitivity in HIV infected children (9). We are 
already seeing that this population has problems of hearing loss beyond and above those seen 
in HIV non-infected children and adolescents (10, 11). 
Despite the widespread and heavy burden of HIV in Sub-Saharan Africa, and evidence 
suggesting that HIV is associated with impairment, there is still insufficient research in this 
area (7, 11, 12). Although some previous studies have been conducted in South Africa, larger 
studies have been advocated for in this population group (8). The specific risk factors for the 
increased rate of hearing loss in HIV-infected children and adolescents are unknown. Future 
studies should therefore evaluate specific risk factors for hearing loss in order to suggest 
meaningful avenues for people living with HIV to manage these challenges (3, 7, 9). Early 
identification of hearing loss in children can provide immense benefits, yet many children 
and adolescents remain unreached (5, 6, 13). This emerging population of children and 





2. Aim and Objectives  
 
The overall aim of this study is to investigate hearing loss in adolescents in South Africa, 
focusing on perinatally HIV-infected adolescents. This study is nested in the Cape Town 
Adolescent Antiretroviral Cohort (CTAAC) Study, whose overall aim is to look at chronic 
disease markers and disease progression in this same population.  
These are the specific aims of the study: 
1) To describe the prevalence of hearing loss in HIV-infected and HIV non-infected 
adolescents in Cape Town, South Africa using screening tools. 
2) To investigate the patterns in the association between hearing loss and perinatal HIV 




3.1. Study Design  
 
This is a cross-sectional, descriptive analysis, nested in the CTAAC Study (protocol 
attached).  
3.2. Characteristics of the Study Population.  
 
Five hundred and fifteen perinatally HIV-infected adolescents who have been on 
antiretroviral therapy (ART) for at least 6 months, and 110 HIV non-infected adolescents, all 
between 9 and 14 years of age, will be included in the analysis. The inclusion and exclusion 
criteria are as per the CTAAC Study as stated below, as well as the adolescents having 






 The inclusion criteria will be made broad so as to provide a generalisable sample of 
participants. 
o The participants will all be between the ages of 9 and 14 years at last birthday. 
o Receiving ART for a minimum of 6 months at recruitment (factors that were 
not considered included exposure to ART via Prevention of Mother to Child 
Transmission (PMTCT), previous ART exposure, and level of viral load 
suppression at enrolment).  
o Child providing assent to participate in the study with the parent/ 
caregiver/legal guardian. 
o Parent/caregiver/legal guardian consent provided. 
o Pure-tone air conduction testing results available. 
 It is anticipated that these criteria will make it possible for >90% of all children in the 
target age range to be eligible participants in the study. 
Exclusion Criteria 
 Failure to have met any of the inclusion criteria listed above. 
o Inability to get informed consent from a parent/caregiver/legal guardian 
(including absence, incapacitation, or refusal regardless of child assent). 
o Child dissent despite parent/caregiver/legal guardian informed consent. 
o No pure-tone air conduction testing results available. 
3.3. Recruitment, Enrolment and Follow-up Care  
 
Adolescents will be recruited in Cape Town over a duration of 1 year from 8 sites, which 
include 4 established services: Gugulethu Community Health Centre, Infectious Diseases 
Clinic (IDC), Red Cross War Memorial Children’s Hospital (RCWMCH), G26 HIV/AIDS 





Hospital and smaller Community Health Centres. Participants will be enrolled at the Clinical 
Research Unit (CRU) at the RCWMCH and other associated facilities. Follow-up visits will 
be ongoing at these centres, where routine HIV care and follow up care will be provided.  
3.4. Research Procedures and Data Collection Methods  
 
This cross-sectional analysis will include all adolescents in the CTAAC study who had 
received an audiometric screening examination at enrolment. Baseline visit information 
(including demographic assessment and medical history), laboratory parameters, and clinical 
examination (including examination of the external ear and otoscopy) will be included.  
3.5. Baseline Visit Information  
 
Questionnaires will be administered to adolescents and their caregiver/guardian. Interviews 
will be run in private by trained, well-experienced counsellors at the CRU at the RCWMC. 
Demographic assessments will be conducted by collecting data on the following: household 
and family structure; caregiver/social history (foster care/orphan status, living arrangements, 
educational history and other relevant socioeconomic status questions).  
The detailed medical histories of all eligible participants will be recorded. These include early 
life history (delivery and perinatal history, including any obstetric complications), exposure 
to PMTCT interventions, HIV related history (ART initiation, regimens, side effects and 
adherence), hospital admissions, history of opportunistic infections including tuberculosis 
(TB) (contacts, treatment, site), and use of drugs for prevention of opportunistic infections. 
ART adherence was deciphered using pill counts and validated tools (visual analogue scale 
and 3-day recall from the caregiver and adolescent were conducted separately).  
Clinical history will be abstracted by trained research assistants on each child using the 





provider site to verify history and dates. In cases where follow-up history or in-depth details 
of acute admission details are needed, these will be extracted from medical records from the 
referral facilities. 
3.6. Clinical Examination  
 
A structured clinical assessment was done on each participant, which consisted of a 
structured physical examination by a senior study nurse with in-depth training and extensive 
supervision from members of senior clinical staff. 
3.7. Laboratory Parameters  
 
Blood samples will be taken by venepuncture for TB screening, HIV viral load testing and 
CD4 count. HIV viral load testing was done using the Abbott Molecular Real-Time HIV-1 
assay at the National Health Laboratory Services laboratory.  
3.8. Special Tests 
 
Screening Hearing Test. The screening hearing test will consist of AC testing for the 
hearing threshold at frequencies of 250Hz, 500Hz, 1000Hz, 2000Hz and 4000Hz in both the 
right and left ears. A threshold of greater than 30dB will be considered a fail. The GSI 18 
Screening-audiometer (a single channel, manual audiometer) (14) will be used. AC will be 
performed according to a standard defined protocol by a trained physician/medical officer in 
a quiet examination room (typically completed at the CRU at the baseline visit or first 
possible opportunity). The quiet examination room has previously been shown to provide 
results comparable to those with noise levels of 50-60dBSPL as recommended. This has been 
shown by comparing participant result in EchoRoom to the quiet examination room. The 





of disabling hearing loss (4). The history, examination and select investigations are 





Table A1 Summary of Selected Variables to be included in Data Analysis  
Variable Type of Variable How Variable is Measured (coded 
value) 
Variable Alternative Form For Analysis if used (code of collapsed 
categories)  
Demographics       






























Caregiver is parent  
Caregiver is not parent  
(1/2) 
(3/4/5) 

















Dependence on social grant 
 






















Medical History     
Previous tuberculosis diagnosis 
 










Antiretroviral regimen (ART) Categorical, nominal 2 X NRTI + NNRTI 






Age at ART initiation  Numerical, 
continuous 










Duration on ART Numerical, 
continuous 




Physical Examination Findings     
Height  Numerical, 
continuous 
Metres (m) - - - 
Weight Numerical, 
continuous 
Kilograms (Kg) - - - 








Right and Left ear external ear 
examination 
Categorical, nominal Normal  





Both ears normal 
Signs of otitis externa/other 
(1) 
(2/3) 
Laboratory Parameters     
Viral load Numerical, 
continuous 
Copies per millilitre - ≤50  









Cells/mm3 - <200  





Percentage CD4 Numerical, 
continuous 




Pure-tone air-conduction(AC) testing     





Minimum response level (MRL)§  Numerical, 
continuous 
Decibels (Db) - - 
 
- 
Pure-tone average(PTA)¥ Numerical, 
continuous 




Hearing loss  Categorical, binary None 











‡ Body mass index (BMI) computed from height (m) and weight (kg), equation:𝑩𝑴𝑰 =
𝒌𝒈
𝒎𝟐
, § MRL is the hearing threshold in decibels which was recorded at each frequency (250 Hz, 500Hz, 






3.8.1. Data Management  
 
No data containing real patient names will be handled during this study (i.e. patient files, 
informed consent forms). All data containing documents and files will have an anonymous 
participant identification number, kept separately from any linking information which will 
not be required for this study. Patient identity will be safeguarded. 
The study manual and standard operating procedure from the CTAAC study will be adhered 
to. Electronic data required for analysis is kept in password-protected files, and only made 
available by the entrusted study team members. All data is stored at the University of Cape 
Town (UCT) within a firewall protected SQL server.    
3.8.2. Data Analysis  
 
Data will be exported to STATA 13 (STATA for Windows, version 13, STATAcorpLP; 
College Station, TX). The statistical analysis will be done in this program by the candidate.  
General: Data exploration of individual variables will be carried out, examining the 
distributions and relevant summary statistics (categorical variables: frequencies, percentage 
frequencies; continuous variables: histograms, means alongside confidence intervals, 
standard deviations, medians, interquartile ranges). Appropriate measures of central tendency 
will be instituted, and used to describe normal and non-normal distributions. 
Associations will be explored between independent and dependent variables (continuous 
variables: scatterplots, correlation analysis; categorical variables: contingency tables, cross-







To address Specific Aim 1:  
 
The prevalence of hearing loss will be calculated in STATA 13 (STATA for Windows, 
version 13, STATAcorpLP; College Station, TX) for the HIV-infected and the HIV 
uninfected adolescents. Ear-specific pure-tone average (PTA) results will be compared by 
adolescent HIV status using the appropriate parametric (t-test)/non-parametric (Wilcoxon 
rank-sum test) test for the two independent groups. The minimum response level will be 
calculated, and every participant will be classified as a pass or fail according to their PTA at 
500Hz, 1000Hz, 2000Hz per ear, with respect to the WHO grades of hearing impairment. 
 
To address Specific Aim 2:  
 
Clinical and other characteristics will be compared between the two adolescent groups with 
and without hearing loss, using Fisher’s exact test or two-sample t-tests, as deemed 
appropriate. Potential factors associated with hearing loss will be evaluated using generalized 
linear models. An appropriate model will be built according to the nature and distribution of 
the dependent variable, and to the study design. The transformation/link function will be 
selected according to the independent and dependent variable relationship. The appropriate 
link function will be selected: an identity link for continuous outcomes, a logit link for binary 
outcomes.   
A manual, backward model selection process will be used to build a model, with hearing loss 
as the outcome variable of interest. This will be done in the presence of baseline demographic 
and clinical characteristics deemed significant. The variable selection process will include 
univariate models for each variable. A conservative p value of 0.2 will be used as a cut-off 
point for variable inclusion into the multivariate model. The model will be run, and variables 





The final model will be selected using appropriate tools, depending on whether the models 
being compared are nested or not. Methods of selection will include the log-likelihood test; 
Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) will also be 
noted. The desire for parsimony will be considered. The final model will be validated 
according to the type of model, to ensure that model assumptions have not been violated.  
3.9. Ethical Considerations 
 
Approval to carry out this analysis as a student mini-dissertation will be obtained from The 
Human Research Ethics Committee of the University of Cape Town, Faculty of Health 
Sciences, South Africa. Approval for the CTAAC Study was obtained prior to 
commencement of the study. The ethics reference number (HREC) is 051/2013 and is due for 
renewal on the 30th of May 2017. This protocol complied with the following:  
o  The Declaration of Helsinki, 2008 
o  The Department of Health: Ethics in Health Research: Principles Structures and 
Processes, 2004 
o  Guidelines for Good Clinical Practice in the Conduct of Clinical Trials in Human 
Participants in South Africa. Second Edition, 2006  
o  Research Involving Children: Standard Operating Procedure: Human Research Ethics 
Committee, Faculty of Health Sciences: University of Cape Town, 2013 




This study will use secondary data. There is no direct contact with study participants and 





1) Risks due to loss of confidentiality due to handling of secondary data of a sensitive 
nature e.g. HIV status.   
All participants will be informed of all possible risks as part of the informed consent process 
in the enrolment phase of the CTAAC study. Risks involved with the CTAAC study will be 
clearly outlined and justified. Relevant measures will be taken to protect against them. 
Protection Against Risks 
 
The risk of any loss of confidentiality will be minimised in various ways. 
1) No data containing real patient names will be handled during this study (i.e. patient 
files, informed consent forms). All data containing documents and files have an 
anonymous participant identification number, kept separately from any linking 
information which will not be required for this study. Patient identity will be 
safeguarded. 
2) The study manual and standard operating procedure from the CTAAC study will be 
adhered to. Relevant measures include: 
a. Electronic data required for analysis will be kept in password-protected files, 
and only made available to the entrusted study team members. All data is 
stored at UCT within a firewall protected SQL server.    
b. No previous incidents of loss of confidentiality have been reported on the 




The study population may not directly benefit from the study. The following are potential 





1) An improved understanding of hearing loss in HIV positive adolescents has the 
potential to improve future health care for this population, particularly in the targeted 
screening and identification of associations to look for during routine care. The 
insight added to this area of currently limited knowledge will affect and possibly 
improve health care in South Africa and beyond.  
 
3.11. Informed Consent Process 
 
No informed consent process will take place for this nested study, as consent/assent has been 
collected in the CTAAC study prior to commencement of the study, in accordance with the 
requirements of the 2012 HSRC Guidelines for research with minors in the participant’s or 
caregiver’s home language (15). 
 
4. Use of Information and Publication 
 
Presentation and/or publication of the study results will be done upon collaboration with the 
CTAAC study investigators. No funding has been involved, and will not impact the results 
presented and/or published in any way. 
The major stakeholders in this research are the adolescent population in Cape Town living 
with HIV. Their participation in the study includes continued attendance to follow-up 
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1. Introduction  
 
Since the advent of Antiretroviral Therapy (ART), the world has seen an increase in 
longevity amongst HIV-infected populations. With this, perinatally HIV-infected (PHIV+) 
children are living into adolescence for the first time in history. This has posed a challenge to 
understanding the effects of chronic HIV-infection and the prolonged use of ART. South 
Africa remains a large contributor to the global HIV burden, and is concurrently situated in 
Sub-Saharan Africa, one of the regions with the highest prevalence of hearing loss in the 
world. Despite the knowledge that hearing loss is common among PHIV+ adolescents, there 
remains limited knowledge about predictors for hearing loss in this population, especially in 
the developing world. Research is highlighting the importance and need for further 
investigation into this unique population with inimitable health needs. 
The aim of this review is to describe the prevalence of hearing loss worldwide in order to 
place the prevalence of hearing loss in PHIV+ adolescents into a global context. The aim is 
also to identify previously investigated predictors for hearing loss in literature, particularly 
those unique to PHIV+ adolescents on ART. A brief outline of basic definitions and concepts 
associated with hearing loss is included in order to provide a background to the summary of 
literature.  
 
2. Literature Search Strategy 
 
The literature search was conducted using Google Scholar and Pubmed online databases. A 
search using Boolean operators and the following search terms was run: 'HIV' AND 'hearing' 
AND 'adolescent'. This also included search word variations in the Pubmed database. The 
literature search was restricted to English language publications published within the last 





article selection. The summary of the selected Pubmed articles is presented in Table B2. 
References of the selected Pubmed publications and existing reviews were searched and 
examined to ensure that all the literature relevant to the literature review objectives were 
reviewed and included by the author. The relevant studies from the extended literature search, 
including Google Scholar search engine results, are summarised in Table B3. 
 
3. Concepts and Definitions 
 
3.1. Hearing Loss 
 
Hearing status is usually quantified according to the lowest intensity of a sound signal that is 
audible to an individual, which is known as the hearing threshold, and measured in decibels 
(dB). The hearing threshold is measured over a range of multiple frequencies that are 
reported in hertz (Hz), and are typically 250Hz, 500Hz, 1000Hz, 2000Hz, 4000Hz and 
sometimes 6000Hz and 8000Hz (1). In adults, abnormal hearing sound thresholds are those 
found to be above 25dB (1,2). In children, the World Health Organisation (WHO) describes a 
sound threshold above 30dB in the better ear as debilitating hearing loss (2). 
3.2. Adolescence 
 
The WHO has defined adolescence to be the phase of critical transition that occurs between 
10 and 19 years of age (3), which has been endorsed by other organisations that have interest 
in the concept of adolescence (4). However, it is accepted that this definition does not address 
the experiences of individuals transitioning from childhood to adulthood, cultural differences 
in shifting from childhood to adulthood, and historical factors that influence the definition of 





3.3. Perinatal HIV Infection 
 
For the purposes of this study, perinatal HIV infection is considered HIV infection via 
vertical infection (mother-to-child). It is presumed that given the age of study participants, 
horizontal routes of infection are unlikely but cannot be ruled out completely, therefore only 
a small percentage of the study participants may have acquired HIV horizontally, eg. 
iatrogenic or sexual. 
 




Pure-Tone Audiometry is considered the gold standard for determining hearing thresholds. 
Audiometry results are traditionally represented graphically using an audiogram. When used 
for both ears, pure-tone audiometry enables configuration, type, symmetry and degree of 
hearing loss to be ascertained (1). Pure-tone audiometry can consist of air-conduction (AC) 
tests, which represent sound through the entire ear, and bone-conduction (BC) tests, which 
represent sound conducted through the inner ear and auditory canal. When AC testing and 
BC testing are used together, the location of a pathological lesion causing hearing impairment 
can be deciphered. In special cases, like auditory neuropathy, hearing loss may require other 
advanced tests such as auditory brain stem responses and auto-acoustic emissions for 
diagnosis (1). There are also other audiologic tests and technologies under investigation(6).  
Classification of Hearing Loss 
 
Classification of hearing loss enables the determination of further test procedures and the 
selection of appropriate interventions (1, 4). It is essential to classify any hearing loss as part 
of an audiometric assessment according to degree, configuration and type. There are three 





Conductive hearing loss occurs when sound is not successfully transmitted through the ear 
canal to the middle ear, whilst sensorineural hearing loss occurs when there is inner ear 
damage, or damage to the nerve pathway connecting the inner ear to the brain (4). Mixed 
hearing loss refers to a combined pathology of conductive and sensorineural hearing loss (1). 
Configuration is determined by the audiogram generated by the AC threshold across the 
frequency spectrum. The terms used to describe hearing loss configuration include (but are 
not limited to): flat, rising, trough, notch, gradually and sharply sloping. These are 
determined by the shape of the audiogram (1). For each ear, the degree of hearing loss is used 
as an indication of hearing loss severity. The degree of severity is calculated using the Air-
Conduction Pure-Tone Average (PTA) at 500Hz, 1000Hz, 2000Hz (1, 4). When hearing loss 
affects one ear (right or left) it is termed unilateral hearing loss. When it affects both ears 
(right and left) it is termed bilateral hearing loss. Hearing loss severity is also measured by 
metrics such as the symmetry of the severity, the onset progression, and the changing severity 
of the hearing loss.  
Causes of Hearing Loss 
 
There are many identified causes of hearing loss, ranging from congenital to acquired causes, 
that vary by hearing loss type. Table B1. shows selected causes of sensorineural and 
conductive hearing loss adapted from Mahomed et. al. (1).   
Table B1 Showing a summary of Selected Causes of Conductive and Sensorineural Hearing 
Loss(1) 
Type of Hearing Loss 
Conductive Hearing Loss Sensorineural Hearing Loss 
Wax impaction in ear canal Congenital infections (e.g. Cytomegalovirus, 
Rubella) 
Tympanic membrane perforation  Acquired infections (including TB, HIV) 
Otosclerosis Ototoxicity (e.g aminoglycosides, cytotoxic 
drugs, antimalarials, loop diuretics) 
Ossicular chain dislocation Noise induced hearing loss 
Cholesteatoma Presbyacusis 






In light of the scope of this literature review, the causes highlighted in the following summary 
will focus on those that concern PHIV+ adolescents. 
 
4. Summary of Literature 
4.1. The Prevalence of Hearing Loss 
 
Over 1.3 billion people are affected by hearing loss worldwide, making hearing loss the 
second highest most prevalent impairment contributing to Years Lost due to Disability (YLD) 
(7). There has been an almost 30% increase in the global prevalence of hearing loss in the last 
10 years (7). Globally, 32 million children are living with disabling hearing loss, with the 
majority coming from low-income and middle-income countries (8).  
In the United States of America (USA), the Third National Health and Nutrition Examination 
Survey (NHANES III) showed that there was a 14.9% prevalence of hearing loss amongst 
young people between the ages of 6 - 19 (9). These estimates raised interest amongst other 
researchers, who re-evaluated the data using alternative methods of analysis (9). Other 
smaller case record reviews of adults in the USA found that the prevalence of hearing loss 
was less than 1% in HIV-infected patients. This finding has, however, been questioned, and 
the very low prevalence of hearing loss in this cohort has been attributed to case records 
lacking information in audiometric testing (10). 
There are various studies worldwide that have investigated hearing loss associated with HIV-
infection. The Paediatric HIV/AIDS Cohort Study (PHACS) investigated hearing loss 
amongst two groups of American adolescents: the first group were HIV-infected, and the 
second were HIV-exposed but uninfected. It was found that 20% of HIV-infected adolescents 





counterparts, and higher than the hearing loss prevalence reported in NHANES III (11). 
Young, healthy, Western populations have shown a percentage of diagnosed hearing loss 
lower than 10% (12).  Even in the early stages of HIV-infection (13), hearing loss is a 
common problem in HIV-infected populations (13-15). A systematic review of evidence 
spanning over 30 years found the prevalence of hearing impairment in Sub-Saharan Africa to 
be 24.1% amongst people living with HIV (14). A Cameroonian study found the prevalence 
of hearing loss in HIV-infected patients to be 27.2%, which was four times higher than the 
HIV-uninfected control group in the same study (15). A study conducted in Johannesburg 
yielded similar results, showing a hearing loss prevalence of 23% among HIV-infected adults 
and 26% among HIV-infected children (16). PHIV+ children in Cape Town had a higher 
hearing loss of 21.6%, in comparison to the 8.3% prevalence of hearing loss HIV- controls. It 
is noteworthy that there is not a significant difference between these two percentages (17). 
Similar studies done in other countries have reported even higher prevalences of hearing loss 
amongst study groups of HIV-infected children and adolescents: 34% in India, 38.8% in Peru 
(18) and 33% in a small cohort of HIV-infected Mexican adolescents (19).  
Projected Increase in the Burden of Hearing Loss 
 
A projected increase in hearing loss in the USA shows that by 2060 almost twice as many 
people in the country will have hearing loss: an increase from 44.11 million to 73.5 million 
hearing impaired individuals. This rate of increase in hearing loss will be faster than the 
population growth rate itself, and is anticipated to put a significant strain on already stretched 
resources (20). 
4.2. Risk Factors for Hearing Loss in Adolescents 
 
Risk factors are noted for hearing loss in adolescents throughout literature, with some 





hearing loss among Chinese children: low parental educational attainment, an income below 
the national average and single-headed households (21). Western studies among HIV-
infected and HIV-uninfected but exposed groups have revealed caregiver race, caregiver IQ, 
caregiver education status, family income and who the primary caregiver was in the home to 
be some of the socio-demographic risk factors for communication related impairments (22). 
Similar socio-demographic predictors have been examined for neurological sequelae in HIV-
infected children in Cape Town, namely Body Mass Index (BMI), ancestry, relationship to 
caregiver and absence of biological parents (23). In HIV-infected Sub-Saharan African 
children, a low BMI, being male and tuberculosis (TB) infection were found to be risk factors 
for hearing loss (24). Previous cerebral infections and a history of seizures in HIV-infected 
children have also been shown to be risk factors for hearing loss (18). 
4.3. Hearing Loss and HIV Related Risk Factors 
 
Type of Hearing Loss in HIV- Infected Populations 
 
It has not been possible to ascertain a typical profile of hearing loss for HIV-infected people, 
as varied audiological manifestations have been found throughout literature (13, 14, 19, 25). 
This heterogeneity is also evident in studies conducted amongst HIV-infected populations in 
South Africa (26). Various audiometric patterns of hearing loss have been found, including 
sensorineural (13, 25, 27), conductive (28) and mixed hearing loss. In the past, among HIV-
infected populations, children have shown conductive hearing loss secondary to middle ear 
pathology more commonly than adults who experienced more sensorineural hearing loss due 
to inner ear pathology (29). 
Aetiology and the Mechanism of Hearing Loss Specific to HIV-Infected Populations 
 
The aetiology of hearing loss in HIV-infected people has been attributed to ototoxic drugs, 





resulting in hearing loss has been proposed as the mechanism through which hearing loss 
may occur, which may be compounded by the synergistic effect of increasing age, NRTI, and  
HIV (30-32). Sub-Saharan Africa in particular has seen a shift in the epidemiology of 
paediatric HIV. PHIV+ are affected by chronic HIV-infection and have long-term ART 
exposure. The effects of aging combined with HIV exposure have manifested in vast 
complications that include, but are not limited to, hearing loss (33). Lin et. al. found an 
increased prevalence of sensorineural hearing loss in HIV- infected people aged 18 to 35, 
which they attributed to HIV-related accelerated biological aging (34). 
Antiretroviral Therapy and Hearing Loss 
 
The use of unspecified ART regimens have been implicated in the increase in hearing loss 
seen among HIV-infected adults in comparison to the lower rates of hearing loss in their 
HIV-infected but ART-naïve counterparts (27). In Australia and America, HIV-infected 
adults on a regimen containing a Nucleoside Reverse-Transcriptase Inhibitor (NRTI) were 
found to have markers of mitochondrial toxicity (32) and associated hearing loss (30). 
Similarly, NRTI use in PHIV+ adolescents was associated with hearing loss in an Australian 
longitudinal study (32). Despite this evidence of the positive association between the use of 
NRTI and the increased risk of hearing loss, the PHACS study did not find an association 
between ART use in PHIV+ adolescents and hearing loss (11, 17). ART therapy was also not 
associated with hearing loss among HIV-infected adults enrolled into the Multicentre AIDS 
Cohort Study (MACS) and the Women’s Interagency HIV Study (WIHS) studies (35). 
Protease Inhibitor (PI) use was not associated with mitochondrial damage in Western 
populations by Cherry et al. and Crain et al. (31, 32). There exist, however, case reports of 
ototoxicity linked to protease inhibitors. For example, a case study of a 44-year-old Hispanic 
patient in Albuquerque showed a possible link between hearing impairment and 





Apart from investigating the ART drug regimen as a predictor for hearing loss, research has 
also been conducted to investigate duration on ART as a predictor for hearing loss. Duration 
on ART was not linked with hearing loss in a case-control study carried out in Cameroon 
(15), neither was a longer duration on ART linked to hearing loss in a small cross-sectional 
analysis by Palacios et al. carried out in Mexico (19). Makar et al. suggested that a longer 
period of time on ART is protective against hearing loss (37). A study conducted amongst an 
HIV-infected Kenyan cohort found that there was an initial worsening of hearing during the 
first six months on ART. However, after this initial period of time, the hearing capabilities of 
the study participants on ART improved and were comparable to those not on ART (38).  
Opportunistic Infections and Hearing Loss in HIV-Infected Individuals  
 
Opportunistic infections manifesting as middle ear effusions are more prevalent in HIV-
infected individuals, as compared to healthy people. This increased prevalence of middle ear 
effusions has been attributed to opportunistic infections due to low CD4 counts in HIV-
infected people (18, 26, 28), and especially so among HIV-infected children (19, 29). At 23% 
among HIV+ children in Johannesburg, South Africa, otitis media was a common finding in 
children suffering from hearing loss (16). Fifteen percent of HIV-infected children had 
opportunistic infections affecting the nervous system in a Cape Town based study, with a 
resultant 6% prevalence of sensorineural hearing loss (23). Low CD4 counts were associated 
with increased hearing impairment in South African adults (26), Peruvian children (18) and 
Mexican children (19). However, low CD4 counts were not seen as predictors for hearing 
loss among PHIV+ adolescents in other geographical regions (11, 19, 34, 39). High viral load 
was associated with poorer cochlear function in PHIV+ children (17). A high viral load was 
also found to be a predictor for generally poor audiological outcomes, (19) but not among 





There is a known relationship between HIV-infection and TB, with a global co-infection rate 
of 13% (7). In Southern Africa, HIV and multi-drug resistant TB co-infection has been noted 
to be as high as 66% in Botswana (42), 46% in Namibia (24), and 30% in South African 
children (43). Culture-confirmed TB diagnosis has been recognised as a risk factor for 
hearing loss in HIV-infected paediatric populations (43), and previous episodes of TB 
infection were common among HIV-infected children in South Africa (23). Certain drugs 
used for the treatment of TB are ototoxic, in particular aminoglycosides like amikacin (24, 
42). Ototoxic TB treatment drugs are associated with a high incidence of hearing loss, and 
have shown a clear dose dependent response between drug dosage, duration of use and 
hearing loss (42). A quarter of children with multi-drug TB infection had hearing loss 
associated with TB drug treatment, and continued to worsen after cessation of treatment (43). 
4.4. Adverse Outcomes of Adolescents with Hearing Loss 
 
Globally, individuals with hearing loss have been found to have delays in speech and 
language acquisition (11), poorer emotional coping mechanisms, and lower academic 
achievement (44, 45). During adolescence, these individuals are also less likely to be 
attending school compared to adolescents who do not suffer from hearing loss (45). 
Furthermore, adolescents with hearing loss are more likely to have behavioural, 
psychological and social difficulties (11, 44). The adverse outcomes of hearing loss are vast 
and have the propensity to negatively affect social and economic development (8). Already, 
PHIV+ adolescents have been shown to be at a higher risk of mental health issues, to perform 
more poorly in general cognitive tests and to have slower processing on visuo-spatial tasks 
than healthy adolescents (46). Rates of learning impairment in HIV-infected and HIV-
uninfected but exposed children are over double (40% and 16% respectively) the rates 





heavy burden of the compounded effects of chronic HIV-infection and the many 








Hearing loss remains an important source of disability. In the developing world where less 
data exist on hearing loss (47), the problem of hearing loss receives inadequate attention, 
despite requiring increased attention, especially among adolescents (48). Furthermore, 
hearing loss is a more frequent occurrence in HIV-infected individuals and HIV-exposed but 
uninfected individuals, as compared to HIV-uninfected and unexposed individuals (11). 
Research efforts are intensifying with PHACS, following-up with the Adult Master Protocol 
(AMP), in order to further understand the first generation of PHIV+ adolescents who have 
survived into adolescence in the era of ART (49). However, this research is not based in Sub-
Saharan Africa, where it has been found that there is possibly the highest double burden of 
HIV-infection and hearing loss in the world (47, 50). Striking findings in a review of 
literature highlight that there is scarce data available about PHIV+ adolescents in developing 
countries, where the double burden of hearing loss and HIV-infection is highest (46). 
A review of literature has suggested that audiological manifestations of HIV-infection in 
developing countries may well differ from manifestations seen in developed countries, due to 
differences in contextual and cultural factors (47). Therefore, it is of great importance that 
there is an increase in research conducted about PHIV+ adolescents and hearing loss in Sub-
Saharan Africa. It is also essential to tailor programmes that are directed at auditory well-
being in PHIV+ adolescents, and to ensure that measures are instated to prevent and manage 
this unique group of individuals (11, 14, 25, 28, 51). Primary (reducing the number of new 
cases of hearing loss), secondary (halting the progression of hearing loss) and tertiary 
(treatment and reduction of the sequelae of hearing loss) prevention strategies are advocated 





Table B2 Showing Summary of Pubmed Search 
In-text 
Citation 
Author, year Setting  Study design  Population and sample 
size 
Objective Findings 






aged between 15-80 
years, attending the 
Otolaryngology Clinic 
at Groote Schuur 
Hospital 
To determine the accuracy 
of the uHear app on the 
iPhone as a screening tool 
for moderate hearing loss at 
multiple frequencies 
The uHear application for iPhone was a 
reasonable screening tool for disabling hearing 
loss. It showed high sensitivity and a high 








Three thousand six 
hundred and forty-six 
HIV-infected patients, 
of median age 37.5 
years 
To describe the prevalence 
of hearing loss amongst 
HIV-infected patients 
enrolled in the Adult 
Spectrum Disease (ASD) 
project 
The prevalence of hearing loss among HIV-
infected adults was less than 1% (exact percentage 
is 0.8%), but the low prevalence could be 
attributed to case records not containing 
information on audiometric assessment 
(11) Torre, 2012 Fifteen sites in 
Puerto Rico 
and the United 
States of 
America  
Cohort study Two hundred and thirty-
one adolescents (145 
HIV positive, 86 HIV 
unexposed) 7-16 years 
old, enrolled in the 
Adolescent Master 
Protocol (AMP) study 
of the Paediatric 
HIV/AIDS Cohort 
Study (PHACS) 
Defining prevalence and 
evaluation of risk factors for 
hearing loss 
HIV-infected participants had increased odds of 
hearing loss compared to HIV-uninfected but 
exposed participants (20% versus 10.5%), and 
both greater than NHANES III estimates. ART 







One hundred and fifty-
three adults and children 
attending the 
outpatient’s HIV clinic 






Otolaryngological manifestations are common 
early presentations of HIV infection. Chronic 
suppurative otitis media was the most common 
otological presenting complaint. Chronic 
suppurative otitis media, otitis media with 
effusion and sensory-neural hearing loss were in 

















One hundred and eighty 
patients aged 15 to 49 
years old 
To investigate hearing loss 
in HIV-infected patients on 
ART, and HIV-infected 
patients not on ART 
HIV+ participants had more otologic complaints 
than HIV- participants. The prevalence of hearing 
loss among HIV+ participants was 27.2%, and 
5.6% in the HIV-uninfected participants. Age, 
sex, CD4 count and duration on ART were not 
found to be predictors for hearing loss among 
HIV- participants. Bilateral hearing loss was 
found in 43% of cases, right sided hearing loss in 
21%, and 36% in left sided hearing loss. 
Sensorineural hearing-loss was the most prevalent 
type of hearing loss (61.7%). ART naïve patients 
had worse hearing than patients on ART 
(17) Torre, 2015 Puerto Rico 





One hundred and 
seventy-two children 
aged 7- 16 years old 
who were born to HIV+ 
mothers, enrolled in the 
PHACS study 
To determine the 
association between HIV 
and distortion product 
optoacoustic emissions 
(DPOEs) 
PHIV+ children and HIV-exposed but HIV-
infected children had similar cochlear function. 
Higher viral load was associated with poorer 
cochlear function in PHIV+ children 




One hundred and thirty-
nine HIV-infected 
children aged 4 to 19 
years 
To investigate predictors for 
hearing loss, and measure 
the prevalence of hearing 
loss among HIV+ children 
in Peru 
The prevalence of hearing loss among HIV-
infected children was 38.8%. Predictors for 
hearing loss in HIV-infected children were low 
CD4 cell count, previous cerebral infection and 









between 5 months and 
16 years of age 
To evaluate vestibular and 
audiologic disorders in 
HIV-infected children on 
ART 
Thirty-three percent of children between 12 and 
16 years old had hearing loss. Chronic suppurative 
otitis media was a predictor for conductive 
hearing loss. Prolonged duration of HIV- 
infection, higher viral load counts and lower 
absolute CD4 counts were predictors for abnormal 
audiological findings. A wide variety of 
audiological manifestations of HIV infection were 
seen among HIV-infected children. Duration of 








Author, year Setting  Study design  Population and sample 
size 
Objective Findings 
(22) Rice, 2012 Puerto Rico 





Four hundred and 
eighty-six HIV-infected 
and HIV-exposed but 
uninfected participants 
aged 7-16 years old 
To quantify risk of language 
impairment in children with 
perinatal HIV-exposure or 
HIV-infection 
There were no differences found between 
caregiver characteristics (marital status, education, 
IQ). HIV-infected children came from higher 
income households than their HIV-uninfected but 
exposed counterparts, they were also more likely 
to come from homes where their own parent was 
their primary care-giver. Children with HIV-
infection or HIV-exposure have high rates (40%) 
of learning impairment compared to the 16% 









aged 2 to 12 years of 
age 
To investigate neuro-
behavioural and neurologic 
complications of HIV1-
infected children 
Six percent of HIV1-infected children had 
sensorineural hearing impairment. Previous 
episodes of TB were common among children 
infected with HIV1. Fifteen percent of 
participants had central nervous system 
opportunistic infections. Over half of the 
participants had behavioural problems 
(24) Sagwa, 2015 Namibia Retrospective 
cohort study  
Three hundred and fifty-
three patients on MDR-
TB treatment 
To quantify risk caused by 
Kanamycin and Amikacin 
in MDR-TB treatment 
Forty-six percent of MDR-TB patients were HIV-
infected as well. The prevalence of any hearing 
loss was 58% in this study. Amikacin proved to be 
a higher risk than Kanamycin for hearing loss. 
Risk factors for hearing loss in this population 
were HIV co-infection, a lower BMI and being 
male 




One hundred and fifty 
HIV-infected adults 
aged between 18 and 55 
years old 
To describe the prevalence 
and type of hearing loss 
among HIV-infected adults 
in Johannesburg 
The prevalence of hearing loss was 23% among 
HIV-infected adults in Johannesburg. Conductive 
and sensorineural hearing loss, with a wide range 
of severity, was found in this population. 
Deterioration of immunological status was 
associated with sensorineural hearing loss. The 
severity of hearing loss was not range-specific. 
Opportunistic infections and their treatment 







Author, year Setting  Study design  Population and sample 
size 
Objective Findings 





adults (24 not on ART, 
32 on ART) 
To compare electro-physical 
manifestations between 
HIV-infected adults on ART 
and HIV-infected adults not 
on ART 
ART exposure was associated with increased 
abnormalities in the brainstem auditory pathway 









infected people and non 
HIV-infected people all 
between 18-45 years old 
and attending the HIV 
clinic at the University 
of Benin Teaching 
hospital 
To use tympanometry to 
compare middle ear 
pathology between HIV-
infected adults and HIV-
uninfected adults 
Middle ear effusion was more common in HIV-
infected adults than in HIV-uninfected adults. 
Middle ear effusion (seen as a type B 
tympanogram) could be the cause for middle ear 
pathology seen in HIV-infected populations, 
although it may not be detected in the absence of 
clinical features of otitis media. Decreasing CD4 
cell counts were correlated with increasing 
presence of middle ear effusions 





One hundred and forty-
eight HIV-infected and 
HIV-uninfected adults 
and children between 3-
50 years of age 
To characterise audiological 
outcomes and Brainstem 
Auditory Evoked Potential 
(BAEP) in adults and 
children with HIV 
There was a high prevalence of hearing loss 
among HIV-infected adults and children. 
Assessments showed that adults had a 
significantly higher prevalence of altered hearing 
than children in the HIV-infected group. Findings 
of middle ear pathology (manifesting as 
conductive hearing loss) were more common in 
children, whilst inner ear pathology (manifesting 
as sensorineural hearing loss) was more common 
in adults in the HIV-infected group 
(37) Makar, 2012 India  Sixty-seven HIV+ 
participants aged 4-16 
years 
To describe the nature of 
speech, language and 
audiological problems 
encountered by children 
with HIV 
Thirty-four percent of HIV infected adolescents 
and children had hearing loss. Communication 
problems were common among HIV-infected 
adolescents and children. Those on ART for 








Author, year Setting  Study design  Population and sample 
size 
Objective Findings 
(38) Makau, 2010 Nairobi, Kenya Case-control 
study 
Two hundred and 
seventy-one HIV-
infected patients on 
ART, and 273 who were 
not on ART 
To determine if ART is 
related to hearing loss 
ART use was not associated with hearing loss, 
despite an initial worsening of hearing in the first 
6 months on ART, that was noted to resolve. 
More patients not on ART (34%) compared to 
those receiving ART (28%). Increasing age was 
associated with hearing loss. The most common 









Three hundred and 
eighty-five participants 
of ages 6-15 years 
To determine the prevalence 
of chronic HIV-related 
morbidity 
Children and adolescents with HIV had a heavy 
burden of chronic disease. There was no 
association found between CD4 count and chronic 
conditions. From self-reporting, 12% of HIV+ 





Four hundred and thirty-
seven patients with 
MDR-TB above 15 
years of age attending 
specialised TB treatment 
centres 
To investigate the effect of 
Amikacin in treating MDR-
TB and risk factors 
associated with hearing loss 
in patients receiving 
Amikacin for MDR-TB 
treatment 
Amikacin was associated with a high incidence of 
hearing loss. Increasing dose, and increasing 






Multiple studies To review evidence on 
neurodevelopmental 
outcomes of PHIV+ 
adolescents 
There is a paucity of research evidence in 
developing countries compared to developed 
nations. Effects of HIV-infection on the 
developing brain are not well understood. PHIV+ 
adolescents have worse neurodevelopmental 






Multiple (exact number 
not stated) 
To review literature with the 
aim of highlighting the need 
for intensified research on 
HIV-infection and its effect 
on auditory function 
Audiological manifestations of HIV-infection are 
heterogeneous. There is a paucity of research on 
hearing loss in developing countries in the HIV-
infected population. It is possible that the results 
of studies done in developed countries do not 
correctly mirror findings in the developing nations 













and the United 
States of 
America 
Protocol for a 
prospective 
cohort study 
Eight hundred young 
men and women 
previously enrolled in 
the PHACS Adolescent 
Master Protocol (AMP) 
study, now planned for 
follow-up in the AMP 
Up study 
To investigate the outcomes 
of PHIV+ adolescents 
during long-term follow-up 








Table B3 Summary of Studies Included in the Extended Search 
In-text 
Citation 
Author, year Setting  Study design  Population and 
sample size 
Objective Findings 
(7) Vos, 2016 Global Systematic review 
and analysis 
(1990-2015) 
Over nine billion 
estimates as part 
of the Global 
Burden of Disease 
(GBD) Study 
To generate assessments 
and provide trends of 
disease and injury sequelae, 
prevalence and years lost to 
disability for 310 
conditions 
The second leading cause of impairment in 
individuals by numbers affected was hearing 
loss. Hearing loss of greater than 20dB affected 
1.33 billion people worldwide. 
HIV/AIDS was one of the main contributors to 
disease burden in regions with a low socio-
demographic index, and in southern Sub-
Saharan Africa, it was found to be the universal 
leading cause of disability. 
 
Global tuberculosis incidence was 10.2 million 
cases in 2015, and higher than the WHO 
estimate of 9.6 million cases in 2014. 13% had 
HIV and tuberculosis co-infection, as opposed 
to WHO estimate of 12% 
(9) Barret, 2015 The United 
States of 
America 







Six thousand one 
hundred and sixty-
six children aged 
6 to 19 years of 
age 
To make refinements to the 
original NHANES III 
analysis by delineating 
permanent hearing loss 
from fluctuating hearing 
loss, and provide an 
emphasis on best ear and 
worst ear thresholds 
Better ear threshold is a superior gauge for 
portraying real disability in children. The 
prevalence of permanent hearing loss was 
1.23%, and fluctuating hearing loss was 0.2% 
at a 16db threshold. Ethnicity and race were 
found to differ in prevalence of hearing loss 











Three million nine 
hundred and 
fifteen thousand 
three hundred and 
sixty infants 
To screen and diagnose 
hearing loss in infants 
Hearing loss was diagnosed in 8.9% of infants 
who failed the screening test 
(14) Banks, 2015 Sub-Saharan 
Africa 
Systematic review 
of literature from 
1980 to 2013 
Sixty-one articles To review the prevalence 
of HIV and disabilities 
amongst adults and 
children  
HIV was linked to an increased risk of 
disability, and significantly lower levels of 
functioning in HIV-infected people. The 
prevalence of hearing impairment was 24.1% 














Pilot study Sixty-two children 
from 18 months to 
6 years old 
To describe the prevalence 
of hearing loss and 
associated clinical findings 
in HIV-infected children 
The prevalence of hearing loss was 26% in 
HIV-infected children, and 23% of these 
participants had otitis media, which was found 
to be the most likely cause for hearing loss 




Six hundred and 
sixteen thousand 
nine hundred and 
forty children 
aged 0-17 years 
old. 
To describe the prevalence 
of hearing loss and identify 
risk factors for hearing loss 
among Chinese children 
The prevalence of hearing loss was 17.49 per 
10,000 which was significantly lower than 
American, Canadian and African populations. 
Children and adolescents between the ages of 
6-17 had significantly higher rates of hearing 
loss than those younger than 6 years of age. 
Risk factors for hearing loss were low parental 
educational attainment, low family income, 
single-head homes 
(25) Araújo, 2012 Multi-country Systematic review Thirty-eight 




To determine the 
occurrence of hearing loss, 
as well as characterise 
hearing loss by degree and 
type, in HIV infected 
individuals 
Hearing loss varied vastly by configuration and 
degree in HIV-infected individuals. It included 
conductive, sensorineural, and mixed hearing 
loss, in addition to vestibular disorders and 
tinnitus. Aetiology was attributed to ototoxic 
drugs, opportunistic infections, and to the virus 
itself 
(30) Simdon, 2001 Denver, 
United States 
of America 
Case series Three adult males 
infected with HIV 
To observe the progression 
of hearing on NRTI 
Tinnitus and hearing loss found in patients 
taking NRTI. Effect of NRTI toxicity could be 
worse in aging populations in combination with 
the HIV virus itself 







nine hundred and 
thirty-one children 
perinatally 
infected with HIV, 




Mitochondrial damage in 
association with ART in 
perinatally HIV infected 
adolescents 
NRTI (Stavudine and Lamuvidine) associated 








Author, year Setting  Study design  Population and 
sample size 
Objective Findings 








To use tissue mitochondrial 
DNA as a marker of NRTI 
(nucleoside analogue 
reverse transcriptase 
inhibitor) toxicity  
Current use of NRTI (Stavudine and 
Didanosine) associated with tissue 
mitochondrial DNA depletion (p<0.0001), but 
no association with protease inhibitor therapy 






To discuss HIV infection in 
adolescents, and the 
changing epidemiology of 
paediatric HIV 
There is a shift of the burden of HIV-infection 
from paediatric populations to adolescent 
populations. PHIV+ adolescents are facing 
distinct chronic health challenges and 
psychological issues 









controls aged 18 
to 35 years old 






sensorineural hearing loss 
in HIV infected adolescents 
and young adults 
Sensorineural hearing loss was associated with 
HIV infection in patients between 18 and 35 
years of age, but not above 36 years of age. 
Sensorineural hearing loss was attributed to 
HIV- related acceleration of biological aging in 
HIV-infected people. Sensorineural hearing 
loss was not associated to the severity or 
progression of HIV infection 




analysis of data 
from cohort study 
Two hundred and 
sixty-two men 
(enrolled in the 
Multicentre AIDS 
Cohort Study 
[MACS]) and 134 
women (enrolled 
in the Women’s 
Interagency HIV 
Study [WIHS])  
To investigate pure-tone 
thresholds in HIV-
uninfected and HIV-
infected adults. To find 
HIV-related factors 
associated to pure-tone 
thresholds 
HIV-infected participants had higher low-
frequency (LPTA) and higher high-frequency 
pure-tone averages (HPTA) in the better ear 
than HIV-uninfected participants (18% and 
12% respectively). The effect of HIV-infection 
on hearing was the same for best and worst ear.    
HIV-related factors (viral load, CD4, CD8, 
ART therapy, AIDS history) were not 
significantly associated with LPTA and HPTA, 
although increased age was associated with 







Author, year Setting  Study design  Population and 
sample size 
Objective Findings 
(36) Williams, 2001 Albuquerque, 
United States 
of America  
Case report One 44-year-old, 
HIV-infected 
Hispanic man 
To report on mitochondrial 
toxicity 
Mitochondrial dysfunction was independently 
associated with Protease Inhibitor (lopinavir-
ritonavor) manifested as hearing impairment 




analysis of data 
from cohort study 
Two hundred and 
sixty-two men 
(enrolled in the 
Multicentre AIDS 
Cohort Study 
[MACS]) and 134 
women (enrolled 
in the Women’s 
Interagency HIV 
Study [WIHS]) 
To compare speech 
audiometry measures 
between HIV-uninfected 
and HIV-infected adults. 
To find HIV-related factors 
associated to speech 
audiometry measures 
Speech recognition thresholds were only 
borderline significantly worse in HIV+ 
participants than HIV-participants. HIV-related 
factors (viral load, CD4, AIDS history) were 
not significantly associated with speech 
audiometry results. In combination with 
findings from this and other research done on 
this cohort, the aetiology of hearing loss in HIV 
is likely due to central auditory processing 
disorders or peripheral auditory neural issues. 
Speech-in-noise testing may be useful in the 
future to compare hearing between HIV-
infected and HIV-uninfected populations 






age of 43 months 
old 
To examine hearing loss in 
children treated for 
multidrug-resistant 
tuberculosis 
Prevalence of hearing loss was 25%, and a 
third were HIV-infected. Culture-confirmed vs 
presumed TB was a risk factor for hearing loss. 
In some cases, hearing loss continued to 
worsen after TB treatment 
(44) Kotby, 2008 Egypt Retrospective 
case-record 
review between 




in the Audiology 
Unit, Ain Shams 
University 
To determine the public 
health impact of hearing 
loss in Egypt 
Eighteen percent of newborns failed screening 
hearing test, of which 4.8% were confirmed to 
have hearing loss on follow-up. Adverse 
outcomes of hearing loss include poor language 
skills, low academic achievement, as well as 
behavioural, psychological, intellectual and 
social problems 







aged 4-14 years of 
age 
To estimate prevalence and 
types of hearing loss in 
HIV-infected children 
Prevalence of hearing loss was 24%, Frequent 
ear infections, ear drainage, TB, severe HIV 
disease, or low BMI increased risk of hearing 
loss. Duration of ART and CD4 count were not 
associated with hearing loss. Hearing loss 
increased risk of school non-attendance and 







Author, year Setting  Study design  Population and 
sample size 
Objective Findings 
(50) Olusanya, 2014 Global  Literature review Not stated To highlight global trends 
of hearing loss from 1985, 
and to map a plan of action 
to tackle hearing loss 
Developing nations, particularly in Africa and 
Asia need to be alerted to the enlarging 
prevalence of hearing loss, and provide 
interventions that tackle the challenge 








To gather data on HIV-
uninfected and PHIV+ 
children in Cape Town 
Hearing loss was higher for PHIV+ children at 
21.6%, but not significantly different to that of 
HIV- children who had an 8.3% prevalence of 
hearing loss. More unilateral hearing loss was 
seen in PHIV+ adolescents 












between 1988 and 
1994 
Six thousand one 
hundred and sixty-
six children aged 
6 to 19 years of 
age 
To describe the prevalence 
of hearing loss and identify 
sociodemographic profiles 
of children with hearing 
loss using pure-tone 
audiometry 
Audiometric screenings revealed that 14.9% of 
participants had high frequency or low-
frequency loss at a 16dB threshold. Most 
hearing loss was unilateral 










above 15 years of 
age 
To evaluate the impact of 
ART scale-up in South 
Africa 
There has been a rapid scale-up of ART in 
South Africa. This has resulted in improved 
primary care, and better health outcomes for 
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To investigate hearing loss among perinatally HIV-infected (PHIV+) adolescents on 




A cross-sectional analysis was carried out to describe the prevalence, nature and predictors 
(demographic, past medical history, clinical findings) of hearing loss in adolescents between 
9 and 14 years of age. Screening pure-tone air-conduction (AC) thresholds above 30 decibels 
(dB) were considered to be indicative of debilitating hearing loss. Statistical analysis included 
univariate analysis and multivariate logistic regression.  
Results 
 
The cross-sectional analysis included data from 540 participants; consisting 273 males (51%), 
267 females, 432 PHIV+ and 108 HIV-, with a median age of 12 years. Hearing impairment 
was observed in 19% of all the adolescents in the study. Multivariate analysis showed the 
following predictors for any hearing loss: an unmarried primary caregiver (odds ratio (OR) 
0.59; 95% confidence interval (CI), 0.39;0.91, p = 0.015), being female (OR 1.67; 95% CI, 
1.12;2.51; p = 0.013) and reports of being troubled by ear pain or discharge in the last month 
(OR 2.54; 95% CI, 1.55;4.17; p = <0.001) after adjustment. Univariate analysis showed an 
association between hearing loss and a longer duration on ART among PHIV+ adolescents 







The prevalence of hearing loss appears to be comparable between PHIV+ and HIV- 
adolescents in Cape Town. In low resource settings, a history of ear pain or discharge within 
the last month may be used as a screening tool for a hearing assessment, and guide referral 























The global prevalence of hearing loss has risen by almost 30% in the last 10 years, now 
accounting for over 1.3 billion people, and ranking as the second most prevalent impairment 
and contributor to years lost due to disability (YLD) worldwide (1). In Sub-Saharan Africa it 
is estimated that a quarter of the population suffers from hearing impairment (2). Children 
make up about 10% of people who live with hearing impairment worldwide, the majority 
living in low and middle income countries (3). 
Preliminary data suggest that significantly higher rates of hearing impairment are reported in 
people living with HIV in comparison to their HIV-uninfected (HIV-) counterparts (4-6). 
However, there exists conflicting evidence that shows hearing loss rates to be similar in HIV-
infected (HIV+) and HIV- populations (7). Ninety percent of all HIV+ children reside in Sub-
Saharan Africa (8), with South Africa being one of the six countries contributing to half of 
the global burden of adolescents living with HIV (9). Notably, half of all children living with 
HIV were accessing ART by 2015 (8). In the era of ART, HIV+ individuals are living longer, 
as evidenced by demographic health surveys across Africa (10). This produces a unique 
group of individuals, including adolescents, who have been chronically infected with HIV 
and exposed to ART over a long period of time (10-12). Hearing loss in this population has 
been attributed to a number of possible causes: drug toxicity, opportunistic infections or the 
HIV virus itself (13). Other risk factors, such as sociodemographic factors, have been 
identified as potential contributors to hearing loss (14). These require further research, 
particularly amongst PHIV+ adolescents (2, 5, 7). 
Children and adolescents with hearing impairments experience learning difficulties and, by 
extension, struggle with academic performance and social integration (3, 15). The 





limits such adverse outcomes (3, 13). There is an urgent need to provide updated means of 
screening and identifying issues such as hearing loss in HIV-infected populations (12, 13, 15, 
16). The objective of this study was to describe the prevalence of hearing loss among PHIV+ 
on ART and HIV- adolescents, as well as to investigate predictors for the hearing loss, using 






This cross-sectional analysis was carried out within the Cape Town Adolescent Antiretroviral 
Cohort (CTAAC) using secondary data. The overall methodology and research aims of the 
CTAAC have been previously described (17). Participants were adolescents receiving ART 
in public sector care recruited from hospitals and primary care clinics and hospitals around 
Cape Town.  
2.2. Participants 
 
Study enrolment ran from July 2013 to February 2015 at the RCWMCH. Cross-sectional 
analysis was confined to all participants enrolled in the CTAAC who possessed consistent 
AC testing results (see Appendix C1 Showing Flow Diagram Showing Participant Selection 
for Analysis). One hundred and eight HIV uninfected and 432 HIV infected adolescents on 
ART between the ages of 9 and 14 were included in the analysis.  
2.3. Measurements 
 
Data for this analysis were derived from Case Record Forms (CRF) containing baseline visit 
information (demographic assessment and medical history), laboratory parameters (HIV 





Past Medical History and Demographic Assessment 
Trained counsellors ran interviews and administered questionnaires to participants and their 
caregivers in a private setting at the CRU. The detailed medical histories of all eligible 
participants were recorded, including disease symptoms, HIV related history (ART initiation, 
regimens) and opportunistic infections such as tuberculosis (TB). Demographic information 
was also collected for each participant. This included their household and family structure, 
caregiver’s social history, living arrangements, educational history, reception of social grants 
and other questions relevant to socioeconomic status. Trained research assistants verified 
each participant’s record by abstracting their clinical history from the medical history 
interview and the medical record documentation from service provider sites and referral 
facilities.  
Physical examination 
Each participant underwent a structured clinical assessment, which included a structured 
physical examination by a trained senior study nurse, with extensive supervision from senior 
members of the clinical staff. The adolescent’s weight and height were measured as a 
component of the routine examination. Calculation of Body Mass Index (BMI) was obtained 
by dividing weight (in kilograms) by the square of height (in meters).  
Laboratory Parameters 
Venepunctures were done to collect blood samples for TB screening, HIV viral load testing 
and CD4 count. Abbott Molecular Real Time HIV-1 assay was used for the HIV viral load 
testing. This was done at the National Health Laboratory Services laboratory.  
Pure-Tone Air-Conduction (AC) Testing  
AC testing was carried out as a screening hearing test, and the minimum response level 
(MRL) was recorded in both the right and left ears at speech-frequency ranges of 250Hz, 
500Hz, 1000Hz, 2000Hz and 4000Hz. Pure-tone average (PTA) was calculated per ear from 





speech frequencies). Ear-specific PTA was used to define hearing loss. In accordance with 
the World Health Organisation (WHO) grades of hearing impairment, a threshold of greater 
than 30dB was considered as debilitating hearing loss (18). Ear-specific PTA was used to 
compare right and left ear for each participant and to classify better ear PTA and worse ear 
PTA. Hearing loss was defined as any hearing loss (in either the right or left or both ears), 
and unilateral hearing loss was defined as better ear PTA < 30dB HL and worse ear PTA ≥ 
30dB HL. The GSI 18 (Grason-Stadler, United States patent (19)), single channel screening 
audiometer was operated according to a standard, defined protocol by a trained physician or 
medical officer. The AC testing took place in a quiet examination room, at the CRU 
(typically at the baseline visit or first possible opportunity). The quiet examination room was 
shown to provide results comparable to those with noise levels of 50-60dBSPL as recommended. This 
was shown by comparing participant result in EchoRoom to the quiet examination room. Participants 
with ear-specific PTA ≥30dB were referred for further audiologic assessment. 
2.4. Analysis 
 
AC testing results were averaged at 500, 1000 and 2000Hz to produce a PTA for the MRL. 
Binary outcome variables of interest included unilateral hearing loss (vs no hearing loss), 
bilateral hearing loss (vs no hearing loss) and any hearing loss (vs no hearing loss) based on a 
MRL threshold of > 30dB. Predictor variables included baseline demographic information, 
past medical history, examination findings and socioeconomic factors. In PHIV+, other 
variables considered included viral load, CD4 count (absolute and percentage), ART regimen, 
age at ART initiation and duration of ART. 
The prevalence of hearing loss was calculated. Bivariate variables were compared between 
the two participant groups (PHIV+ and HIV-) using the appropriate statistical test (chi-
squared test or Fisher’s exact test). The Wilcoxon rank-sum test for two independent groups 





compared between continuous baseline variables using the ANOVA or Kruskal-Wallis test. 
Initial multivariable logistic models included all covariates with a p < 0.20 level of 
significance in univariate logistic models. Logistic regression models were used to assess the 
impact of variables that were associated (p < 0.05) with hearing loss (any, unilateral or 
bilateral). Confounders were adjusted for by inclusion in the final logistic regression models. 
All calculations were carried out with STATA 13 (STATA for Windows, version 13, 




Ethics committee approval was granted for the cross-sectional analysis by the University of 
Cape Town, Faculty of Health Sciences Human Research Ethics Committee (HREC), 
reference number 088/2017. Informed consent/assent was granted for the parent study in 
accordance with the 2012 Human Sciences Research Council (HSRC) guidelines for research 





The cross-sectional analysis included data from a total of 540 participants (see Appendix C2). 
Just over half (n=273, 51%) were male, with a median BMI of 17.3 (IQR16.1-19.3) and a 
median age of 12 years (IQR10.6-13.3.) The majority of participants were black, Xhosa-
speaking adolescent students. Most households were recipients of social grants and run by a 





4.1. Baseline Characteristics Stratified by HIV Status 
 
Demographic and clinical features of the 540 participants stratified by HIV status (432 
PHIV+ (80%) and 108 HIV- (20%)) are presented in Table C1. There were no coloured HIV- 
participants whilst 37 (9%) of the PHIV+ were coloured. Only PHIV+ participants had 
abnormal external ear examination findings suggestive of otitis externa. Three participants 
had no response for current school status, and so were considered as attending school. Less 
than half of all caregivers were married, and the majority had not achieved tertiary education. 
PHIV+ and HIV- participants were similar by age, gender and school attendance, but differed 
significantly by BMI, language spoken at home, relationship to primary caregiver, primary 
caregiver marital status and educational level. PHIV+ adolescents had a lower median BMI 
of 17.1 compared to HIV- adolescents who had a median BMI of 18.6. The PHIV+ 
adolescent group had twice the proportion of their own parents as primary caregivers, 
compared to HIV- adolescents. HIV- adolescents were more likely to come from a primarily 
Xhosa-speaking household. A third of PHIV+ participants (n=149) had a history of previous 
TB diagnosis, whilst only 2 (2%) HIV- participants had a history of TB, p<0.001.  
The majority of PHIV+ 160 (38%) had commenced ART before 2 years of age and three 
quarters (n=330) were virally suppressed (viral load of ≤50cells/ml), and immunocompetent 
with a CD4 count ≥500cell/mm3. Sixty-one percent (n=259) of PHIV+ participants were on a 
Highly Active Antiretroviral Therapy (HAART) regimen without a Protease Inhibitor (PI). 
4.2. Hearing Loss 
 
Appendix C2 shows that the prevalence of any hearing loss among all participants was 19% 
(n=105). Fifteen percent of hearing loss was unilateral (n=82) and 11% was bilateral (n=61). 





(n=51) for none, unilateral and bilateral hearing loss in PHIV+, and 79% (n=85), 12% (n 
=13), 9% (n =10) in HIV-, p=0.392. 
The prevalence of hearing loss was similar amongst PHIV+ and HIV- adolescents, at 20% 
(n=88) and 16% (n=17) respectively, p=0.277. The median PTA of all ears was 20 (IQR15.0-
27.5) and 23 (IQR15.0-27.5) for PHIV+ and HIV- respectively, p=0.961. Unilateral hearing 
loss was 16% (n=69) and 12% (n=13) for PHIV+ and HIV- adolescents. Despite PHIV+ 
having a higher percentage of unilateral and bilateral hearing loss than HIV- adolescents, the 
difference was not significant, p=0.392. Similarly, the median hearing thresholds were also 
alike for right, left, best and worst ear in PIV+ and HIV- participants. The prevalence of right 
ear hearing loss was 19% (n=81) in PHIV+, 14% (n=15) in HIV-, p=0.237. Left ear hearing 
loss was 21% (n=90) in PHIV+, 17% (n=18) in HIV-, p=0.333. The median PTA for the best 
ear was 17dB (IQR11.7-23.3) for PHIV+, and 18dB (11.7-22.5) for HIV- (p = 0.961). 
Median PTA for the worst ear was 23dB (18.3-33.3) in PHIV+, and 25dB (16.7-30.0) in 
HIV- (p=0.971). 
Table C2 shows PTA (average of 500Hz, 1000Hz, 2000Hz) and MRL for each frequency 
(250 Hz, 500Hz, 1000Hz, 2000Hz and 4000Hz) by side of ear, best and worst ear stratified 
by HIV status. The median MRL values for thresholds at 250Hz, 500Hz, 1000Hz, 2000Hz 
and 4000Hz did not differ significantly between PHIV+ and HIV- participants, although 
thresholds had a vast range between -10dB and 85dB. 
Figures C1.a and C1.b graphically represent trends in hearing thresholds according to 
frequencies that were recorded in Table C2. Figures C1.a and C1.b show a gradual decrease 
of MRL as frequency increases in right, left, best and worst ears for both PHIV+ and HIV-, 
therefore indicating a general improvement of hearing at higher frequencies. However, HIV- 





Table C3 shows the proportions of participants who experienced no hearing loss in contrast to 
those who had unilateral or bilateral hearing loss. The median PTA was worst for those with 
bilateral hearing loss, compared to those with unilateral hearing loss, with a 12dB sound 
threshold difference, p<0.001. There was a difference in the proportions of unilateral, 
bilateral and no hearing loss between participants who had or had not experienced ear pain or 
discharge in the past month, p<0.001. Among PHIV+, later commencement on ART was 
more common among those with no hearing loss (5 years IQR2.1-7.8), compared to those 
with unilateral (3.4 years IQR1.3-6.8) and bilateral hearing loss (3 years IQR1.7-5.2), 
p=0.009. In accordance with these findings, those with no hearing loss had a shorter duration 
(7 years IQR4.3-9.3) on ART than participants with unilateral (8 IQR5.4-9.3) and bilateral 
hearing loss (8 IQR7.1-9.1), p=0.024. 
4.3. Predictors of Hearing Loss 
 
Table C4 shows the adjusted multivariate model for any hearing loss. Among all 
participants, females (OR=1.67, 95%CI=1.12; 2.51, p=0.013) and those who reported 
having been troubled by ear pain or discharge in the past month (OR=2.54, 95%CI=1.55; 
4.17, p=<0.001) were more likely to experience hearing loss. Participants with single 
caregivers (OR=0.59, 95%CI=0.39; 0.91, p=0.015) had a lower risk of experiencing any 
hearing loss. 
HIV infection was not found to be a predictor for any hearing loss according to the univariate 
analysis, p=0.174. A past history of TB was not identified as a risk factor for hearing loss among 






Table C1 Demographic Variables Stratified by HIV- Infection Status of Study Participants  
  Participants (n = 540)   
Baseline variable  HIV Infected (n=432) HIV Uninfected (n=108) P value 
Demographics       
Sex–no. (%) Male 225 (52)     48      (44)  
 Female 207 (48) 60 (56) 0.156 
Median age-yr. (IQR)  12.0  (10.6-13.3) 11.7  (10.1-13.5) 0.425 
Age Category –no. (%) <12 years 220 (51) 56 (52) 
 ≥12 years 212 (49) 52 (48) 
Median BMI- (IQR)  17.1 (15.9-18.9) 18.6 (16.7-21.4) <0.001 
BMI category –no. (%) <18.5 304 (70) 52 (48) 
 ≥18.5 128 (30) 56 (52) 
Race–no. (%) Black 395 (91) 108 (100) 
 Coloured 37 (9) 0 (0) 
Socioeconomic Factors       
Primary language spoken at home–no. (%) IsiXhosa 371 (86) 104 (96) 
 Afrikaans/English/Sesotho/Other 61 (14) 4 (4) 
Current+ caregiver–no. (%) Parent 269 (62) 34 (31) 
 Not parent 163 (38) 74 (69) 
Caregiver marital status–no. (%)       Married 134 (31) 45 (42) 
 Divorced/Single/Other 298 (69) 63 (58) 
Caregiver level of education–no. (%) Below tertiary 385 (90) 84 (83) 
 Above Tertiary 43 (10) 17 (17) 
Dependence on social grant–no. (%) Yes 366 (86) 81 (78) 
 No 62 (14) 23 (22) 
Currently still in school–no. (%)++ Yes   425 (98) 108 (100) 
 No 7 (2) 0 (0) 
Medical History       
Previous diagnosis of TB–no. (%) Yes 149 (34) 2 (2) 
 No 283 (66) 106 (98) 
Experienced ear discharge/ear pain - no. (%) Yes 75 (17) 12 (11) 
 No 357 (83) 96 (89) 
Physical Examination       
External ear examination left an1d right ear Both ears normal 415 (96) 108 (100)  
 Sign of otitis externa 17 (4) 0 (0) 0.031 
Audiometry -Pure Tone Air Conduction Testing(AC)       
Prevalence of hearing loss(PTA>30dB)– no. 
(%)‡ 
105(19)      
Presence of hearing loss(PTA>30dB)– no. 
(%) 
None 344 (80) 91 (84)  
 Any (bilateral or unilateral) 88 (20) 17 (16) 0.277 
Presence of hearing loss(PTA>30dB)– no. 
(%) 
None 312 (72) 85 (79)  
 Unilateral 69 (16) 13 (12)  
 Bilateral (Better ear >30dB) 51 (12) 10 (9) 0.392 
Median PTA of all ears-dB (IQR)  20 (15.0-27.5) 23 (15.0-27.5) 0.961 





 Right ear PTA >30 dB 81 (19) 15 (14) 0.237 
 Left ear PTA ≤ 30 dB 342 (79) 90 (83)  
 Left ear PTA >30 dB 90 (21) 18 (17) 0.333 
Median PTA by side of ear -dB (IQR) Right 20 (13.3-26.7) 22.5  (15.0-28.3) 
 Left 20 (15.0-28.3) 20 (13.3-26.7) 
Median PTA by best and worst ear- dB 
(IQR) 
Best ear 17 (11.7-23.3) 18 (11.7-22.5) 
 Worst ear 23 (18.3-33.3) 25 (16.7-30.0) 
HIV Related Information       
Median CD4 percentage- % (IQR)  30 (24.5-34.4)    
CD4 percentage – no. (%)  <25% 115 (27)   
 ≥25% 317 (73)   
Median absolute CD4 count-cells/ mm3 
(IQR) 
 727 (578.0-972.0)    
Absolute CD4 count– no. (%)  <200 cells/mm3 12 (3)   
 ≥200 - <500 cells/mm3 55 (13)   
 ≥500 cells/mm3 365 (84)    
Median viral load- copies per millilitre (IQR)  40 (40.0-40.0)    
Viral load– no. (%) ≤50 copies per millilitre 330 (76)   
 >50 - <1000 copies per millilitre 47 (11)   
 ≥1000 copies per millilitre 55 (13)    
Median age at ART Initiation-yrs. (IQR)  4 (2.0-7.5)    
Age at ART Initiation-- no. (%) 0-2 160 (38)    
 3-5 112 (26)    
 6-14 151 (36)    
Median duration on ART- yrs. (IQR)  8 (4.7-9.2)    
Duration on ART – no (%) < 8  229 (53)    
 ≥ 8  203 (47)    
ART regimen  2 X NRTI + NNRTI 259 (61)    
 2xNRTI + PI 157 (37)    
 Other* 8 (2)    
IQR =interquartile range; no.= number; yr. =years; CI = confidence interval; n = number; BMI = body mass index; TB= Tuberculosis; PTA = average of minimum response levels/pure tone air conduction 
threshold at 500Hz, 1000Hz, 2000Hz; ART= antiretroviral therapy; ‡In both PHIV+ and HIV- adolescents; †Ear discharge or pain in the last four weeks; *Other ARV regimen = 5 participants lamivudine, 2 
participants Lamivudine-Darunavir-Raltegravir-Ritonavir, 1 participant Abacavir-Zidoudine-Lamivudne, NRTI = nucleoside reverse-transcriptase inhibitor; NNRTI= non-nucleoside reverse-transcriptase inhibitor 







Table C2 Showing Baseline Pure Tone Air Conduction Threshold Results for Right, Left, Best and Worst Ear Decibels by HIV-Infection Status 
  Participants (n = 540)      
 
 
HIV Infected (n=432) 
 
 




HIV Infected (n=432) 
 
































BEST EAR  
 
RIGHT EAR  
27 (11) 25 0,60 28 (11) 30 0,55 0.359  182 (42) 31 (12) 30 0,70 56 (52) 33 (11) 35 5,55 0.060 
                       
25 (10) 25 -5,60 25 (10) 25 0,50 0.838  134 (31) 29 (12) 25 5,75 41 (38) 29 (10) 30 5,50 0.202 
                       
17 (11) 15 -5,65 16 (10) 15 0,50 0.907  63 (15) 21 (13) 20 -5,75 13 (12) 21 (10) 20 0,55 0.206 
                       
13 (11) 10 -5,65 13 (10) 10 -5,60 0.780  57 (13) 17 (13) 15 -5,75 9 (8) 17 (11) 15 -5,60 0.328 
                       
10 (11) 8 -10,60 8 (9) 5 -10,35 0.349  54 (13) 14 (13) 10 -10,70 5 (5) 12 (11) 10 -10,50 0.196 
                       
PTA 19 (10) 17 3,60 18 (9) 18 2,47 0.961  81 (19) 23 (12) 20 3,72 15 (14) 22 (9) 23 2,50 0.211 
 
 
WORST EAR  
 
LEFT EAR  
35 (13) 35 5,70 35 (11) 35 5,60 0.813  200 (46) 31 (13) 30 0,70 47 (44) 30 (11) 30 0,60 0.436 
                       
33 (13) 30 5,75 32 (9) 30 10,50 0.770  149 (34) 29 (12) 28 -5,75 32 (30) 27 (10) 25 0,50 0.276 
                       
25 (14) 20 5,75 24 (11) 25 5,55 0.938  71 (16) 21 (13) 20 0,70 13 (12) 19 (11) 20 0,50 0.258 
                       
22 (15) 20 -5,85 21 (12) 20 0,75 0.870  60 (14) 18 (14) 15 -5,85 14 (13) 16 (13) 13 -5,75 0.208 
                       
4000 19 (15) 15 -10,80 16 (13) 15 -10,70 0.199  55 (13) 15 (15) 10 -10,80 8 (7) 13 (13) 10 -10,70 0.391 
                        
PTA 27 (13) 23 7,73 25 (9) 25 7,50 0.971  90 (21) 23 (12) 20 3,73 18 (17) 21 (10) 20 3,48 0.300 

























Figure C1.a Showing Mean Decibels at Each Frequency 
for Right and Left Ear in HIV-Infected and Uninfected 
Participants
HIV Infected Right Ear HIV Infected Left Ear
















Figure C1.b Showing Mean Decibels at Each Frequency 
for Best and Worst Ear in HIV-Infected and HIV 
Uninfected Participants
HIV Infected Best Ear HIV Infected Worst Ear





Table C3 Showing Characteristics of 540 Participants by Hearing Loss 
  All Participants (n = 540)    
Baseline variable  No Hearing Loss 
(n=397) 
Unilateral Hearing Loss 
(n=82) 
Bilateral Hearing Loss 
(n=61) 
P value 
Demographics         
Sex–no. (%) Male 213 (54) 35 (43) 25 (41) 
 Female 184 (46) 47 (57) 36 (59) 
Median age-yr. (IQR)  12 (10.7-13.4) 12 (10.3-13.2) 12 (10.3-13.0) 0.186 
Age Category –no. (%) <12 years 196 (49) 44 (54) 36 (59) 
 ≥12 years 201 (51) 38 (46) 25 (41) 
Median BMI- (IQR)  17 (16.1-19.3) 17 (15.6-19.2) 17 (15.8-19.2) 0.423 
BMI category –no. (%) <18.5 259 (65) 54 (66) 43 (70) 
 ≥18.5 138 (35) 28 (34) 18 (30) 
Race–no. (%) Black 367 (92) 76 (93) 60 (98) 
 Coloured 30 (8) 6 (7) 1 (2) 
Socioeconomic Factors         
Primary language spoken at home–no. (%) IsiXhosa 348 (88) 71 (87) 56 (92) 
 Afrikaans/English 
/Sesotho/Other 
49 (12) 11 (13) 5 (8) 
Current caregiver–no. (%) Parent 226 (57) 43 (52) 34 (56) 
 Not parent 171 (43) 39 (48) 27 (44) 
Caregiver marital status–no. (%)       Married 122 (31) 36 (44) 21 (34) 
 Divorced/Single/Other 275 (69) 46 (56) 40 (66) 
Caregiver level of education–no. (%) Below tertiary 339 (87) 75 (94) 55 (92) 
 Above Tertiary 50 (13) 5 (6) 5 (8) 
Dependence on social grant–no. (%) Yes 331 (85) 69 (85) 47 (78) 
 No 60 (15) 12 (15) 13 (22) 
Currently still in school–no. (%)++ Yes   391 (98) 82 (100) 60 (98) 
 No 6 (2) 0 (0) 1 (2) 
Medical History         
Previous diagnosis of TB–no. (%) Yes 104 (26) 26 (32) 21 (34) 
 No 293 (74) 56 (68) 40 (66) 














 No 347 (87) 58 (71) 48 (79) 
Participant sero-status HIV-infected 312 (79) 69 (84) 51 (84)  
 HIV-uninfected 85 (21) 13 (16) 10 (16) 0.392 





External ear examination left and right ear Both ears normal 387 (97) 79 (96) 57 (93)  
 Signs of otitis externa 10 (3) 3 (4) 4 (7) 0.189 
Audiometry-Pure Tone Air Conduction Testing(AC)         
Median PTA of all ears-dB (IQR)  18 (13.3-21.7) 31 (27.5-34.2) 43 (36.7-48.3) <0.001 
  HIV Infected Participants (n=432) 
  No Hearing Loss Unilateral Hearing Loss Bilateral Hearing Loss  
  (n=312) (n=69) (n=51) P value 
HIV Related Information         
Median CD4 percentage- %(IQR)  30 (24.0-34.2) 31 (25.2-33.8) 30 (25.9-37.4) 0.357 
CD4 percentage- no. (%)  <25% 87 (28) 17 (25) 11 (22) 
 ≥25% 225 (72) 52 (75) 40 (78) 
Median CD4 count- cells/mm3 (IQR)  714 (555.0-933.0) 733 (615.0-1093.0) 773 (602.0-1031.0) 0.123 
CD4 count- no. (%) <200 cells/mm3 10 (3) 1 (1) 1 (2) 
 ≥200 - <500 cells/mm3 44 (14) 5 (7) 6 (12) 
 ≥500 cells/mm3 258 (83) 63 (91) 44 (86) 0.491 
Median viral load- copies/millilitre (IQR)  40 (40.0-40.0) 40 (40.0-40.0) 40 (40.0-40.0) 0.386 
Viral load- no. (%) ≤50 copies per millilitre 234 (75) 56 (81) 40 (78) 
 >50 - <1000 copies per millilitre 36 (12) 8 (12) 3 (6) 
 ≥1000 copies per millilitre 42 (13) 5 (7) 8 (16) 0.441 
Median age at ART Initiation-yrs. (IQR)  5 (2.1-7.8) 3.4 (1.3-6.8) 3 (1.7-5.2) 0.009 
Age at ARV Initiation-- no. (%) 0-2 106 (35) 28 (42) 26 (52)  
 3-5 83 (27) 16 (24) 13 (26)  
 6-14 117 (38) 23 (34) 11 (22) 0.126 
Median duration on ART- yrs. (IQR)  7 (4.3-9.3) 8 (5.4-9.3) 8 (7.1-9.1) 0.083 
Duration on ART – no (%) < 8  178 (57) 30 (43) 21 (41)  
 ≥8 134 (43) 39 (57) 30 (59) 0.024 
ART regimen – no (%) 2 X NRTI + NNRTI  196 (64) 39 (58) 24 (48)  
 2xNRTI + PI 107 (35) 27 (40) 23 (46)  
 Other * 4 (1) 1 (1) 3 (6) 0.073 
IQR =interquartile range; no.= number; yr. =years; CI = confidence interval; n = number; BMI = body mass index; TB= Tuberculosis; PTA = average of minimum response levels/pure tone air conduction 
threshold at 500Hz, 1000Hz, 2000Hz; ART= antiretroviral therapy; †Ear discharge or pain in the last four weeks, *Other ARV regimen = 5 participants lamivudine, 2 participants Lamivudine-Darunavir-







Table C4 Univariate and Adjusted Associations (Logistic Regression Models) Among all participants and HIV- Infected Participants for Binary 
Outcome of Any Hearing Loss   
 
All Participants (HIV Infected and HIV Uninfected, n= 540) 
 Univariate Regression Model  Adjusted Regression Model 
Variable N Odds Ratio 95% Confidence Interval P Value  N Odds Ratio 95% Confidence Interval P Value 
Body Mass Index ≥18.5 539 0.89 (0.59; 1.33) 0.575  - - - - 
Age   ≥12 yr. 540 0.76 (0.52; 1.12) 0.178  529 0.80 (0.54;1.20) 0.286 
Female 540 1.60 (1.09; 2.36) 0.017  529 1.67 (1.12;2.51) 0.013 
Coloured 540 0.63 (0.27; 1.47) 0.284  - - - - 
Not IsiXhosa speaking  540 0.89 (0.49; 1.63) 0.716  - - - - 
Participants has had TB 540 1.37 (0.91;2.09) 0.128  529 1.22 (0.77;1.92) 0.396 
Participant currently in school 540 2.18 (0.26; 18.26) 0.473  - - - - 
Primary caregiver is parent 540 0.88 (0.60; 1.30) 0.525  - - - - 
Caregiver no tertiary education 529 1.92 (0.94; 3.89) 0.072  529 1.83 (0.88;3.80) 0.103 
Caregiver not married 540 0.67 (0.45    1.00) * 0.047  529 0.59 (0.39;0.91) 0.015 
Household has no grant  532 1.19 (0.71; 1.98) 0.508  - - - - 
Troubled by ear pain/discharge† 540 2.42 (1.50; 3.90) <0.001  529 2.54 (1.55;4.17) <0.001 
Any otitis externa/other 540 1.99 (0.74; 5.34) 0.171  529 2.09 (0.75;2.35) 0.159 
HIV infected§ 540 1.42 (0.86; 2.36) 0.174  529 1.33 (0.06;0.37) 0.318 
 
Restricted to HIV Infected Participants (n=432) 
 Univariate Regression Model  Adjusted Regression Model 
Variable N Odds Ratio 95% Confidence Interval P Value  N Odds Ratio 95% Confidence Interval P Value 
% CD4 ≥25 432 1.27 (0.78;2.07) 0.338  - - - - 
Duration of ART ≥ 8 yr. 432   1.80 (1.17;2.75) 0.007  417 1.91 (0.92;3.97) 0.083 
CD4 Count (vs<200 cells/mm3) 432     -    
≥200 - <500 cells/mm3  1.25 (0.24;6.55) 0.792  - - - - 
≥500 cells/mm3  2.07 (0.45;9.62) 0.352  - - - - 
Viral load (vs ≤ 50 cells/ml) 432     - - - - 
>50 - <1000 copies per millilitre  0.74 (0.36;1.52) 0.420  - - - - 
≥1000 copies per millilitre  0.75 (0.39;1.47) 0.407  - - - - 
Age at ART initiation (vs 0 -2 yr.) 423     417    
3-5 yr.  0.69 (0.40;1.17) 0.167   0.76 (0.38;1.51) 0.437 
6-14 yr.  0.57 (0.34;0.94) 0.029   1.18 (0.46;3.04) 0.731 
ARV regimen (vs 2XNRTI +NNRTI) 424     417    
2xNRTI + PI  1.45 (0.94;2.26) 0.095   1.31 (0.78;2.19) 0.295 
Other regimen   3.11 (0.76;12.80) 0.116   2.09 (0.41;10.11) 0.383 
Body Mass Index ≥18.5 432 0.92 (0.57;1.46) 0.714  -    
Age   ≥12 yr. 432 0.73 (0.48;1.11) 0.139  417 0.76 (0.44;1.31) 0.327 
Female 432 1.48 (0.97;2.26) 0.068  417 1.62 (1.01;2.61) 0.045 
Coloured 432 0.58 (0.25;1.36) 0.213  417 0.64 (0.25;1.65) 0.354 
Not IsiXhosa speaking  432 0.91 (0.49;1.69) 0.771  -    
Participants has had TB 432 1.33 (0.86;2.05) 0.205  417 1.38 (0.85;2.23) 0.196 
Participant currently in school 432 3.53 (0.44;28.20) 0.233  417 11.50 (1.16;113.90) 0.037 
Primary caregiver is parent 432 0.88 (0.57;1.35) 0.546  - - - - 





Caregiver not married 432 0.54 (0.35;0.84) 0.007  417 0.49 (0.29;0.80) 0.004 
Household has no grant  428 1.50 (0.85;2.66) 0.160  417 2.10 (1.07;4.12) 0.030 
Troubled by ear pain/discharge 432 2.80 (1.67;4.69) <0.001  417 3.48 (1.96;6.18) <0.001 
Any otitis externa/other 432 1.87 (0.70;5.03) 0.215  417 2.71 (0.94;7.86) 0.066 
*upper limit raw figure = 0.9954423 §HIV infection was adjusted for despite not meeting the 0.2 level of significance as it was a variable of particular interest in this study, †Ear discharge or pain in the last 





5. Discussion  
 
The adverse outcomes of unidentified hearing loss in adolescents are well established (3, 13, 
15). We assessed the prevalence and predictors of hearing loss among HIV- and PHIV+ 
adolescents on ART in Cape Town, South Africa. The prevalence of hearing loss was high 
regardless of HIV sero-status. Being female, having a married caregiver and a history of 
earache or ear discharge in the past month were positive predictors of hearing loss among all 
participants. Among PHIV+, an additional predictor of hearing loss was having a married 
caregiver without tertiary education. A longer period of time on ART, with an earlier age of 
inception, were associated with hearing loss in the univariate analysis, but the relationship 
disappeared in the adjusted model. 
The prevalence of hearing loss in PHIV+ adolescents in this analysis was 20% (n=88), which 
was similar to earlier reports among the HIV-infected adolescents in the Pediatric HIV/AIDS 
Cohort Study (PHACS) (5), but slightly lower than that of PHIV+ adolescents in Malawi, 
where almost a quarter of the population was found to have hearing impairments (15). This 
discrepancy may be best explained by the lower threshold used in the study done in Malawi 
compared to our study (20dB versus 30dB), allowing for milder cases of hearing loss to be 
included in the Malawian statistics.   
By contrast, the prevalence of hearing loss in our analysis was comparable between PHIV+ 
and HIV- participants, whilst it was significantly lower among the HIV- participants included 
as a comparison group in PHACS (5). The most plausible reason for the comparative 
prevalence of hearing loss between PHIV+ and HIV- adolescents in our study is that the two 
groups were very similar, as they came from the same source population and thus it probably 





The PHIV+ participants had been on ART for a significant period of time, and were relatively 
well controlled, which may have reduced their risk of hearing loss from causes such as 
chronic otitis media. They therefore experienced the same rates of hearing loss as their HIV- 
counterparts. Another possibility, albeit speculative, is that a proportion of the adolescents in 
this cross-sectional analysis were HIV-uninfected but HIV-exposed, therefore increasing their 
chances of hearing loss. This exposure may cause the prevalence of hearing loss among the 
HIV- group to be comparable to PHIV+ adolescents. It has been shown that HIV-exposed but 
HIV-uninfected adolescents have a higher risk of hearing loss (5). It is noteworthy that 
healthy populations of North American children have been found to have hearing loss rates of 
less than 10% (21) compared to the HIV- South African participants who have a hearing loss 
rate of 16%. 
In keeping with previous research, we found that a history of ear discharge was associated 
with hearing loss in PHIV+ children (15). This pattern is consistent with findings from other 
studies of PHIV+ adolescents in Sub-Saharan Africa, in which frequent ear infection has been 
shown to cause hearing loss. Similarly, as seen in the PHACS, our analysis showed that 
caregivers who attained lower levels of education were a predictor of hearing loss in 
adolescents (5).  
In the univariate analysis, a longer period of time on ART was associated with hearing 
impairment in PHIV+ participants. However, this association did not remain consistent after 
an adjustment for confounders. However, previous studies have identified the use of 
Nucleoside Reverse-Transcriptase Inhibitor (NRTI) (22-24) and Protease Inhibitor (PI) (25) 
as risk factors for hearing loss. In addition, unlike other investigators who identified being 
male and having a single parent caregiver as sociodemographic risk factors for hearing loss 





explanation could be that the underlying population structure differs between the two study 
locations (China versus South Africa.) 
Our study is limited by our reliance on AC testing and our lack of Bone Conduction (BC) 
testing. Whilst AC testing represents conducted sounds through the full auditory system 
(inner, middle, external ear, and auditory nervous system), BC testing represents sound 
thresholds of the auditory nervous system inner ear. Using AC and BC testing in combination 
allows for a differentiation between external and middle ear pathology, versus the cochlea 
and central auditory pathway (26). However, the AC testing conducted in this study was 
intended to function as a screening procedure rather than a diagnostic test, and nevertheless 
worked to identify participants with hearing impairments. It also enabled the referral of 
participants who required further audiological evaluation.  
A further limitation of this analysis is that the study only investigated the current ART 
regimen as a predictor of hearing loss. This did not, however, preclude the possibility that 
past ART regimens may have been risk factors for hearing loss. The use of NRTI and PI (25) 
have been associated with mitochondrial damage in PHIV+ adolescents, and thus hearing loss 
(22, 23). We focused on ART exposure at large and did not explore individual agents. 
Additionally, patients who underwent AC testing whilst experiencing otitis media may have 
affected hearing test results. 
In health care facilities, routine assessments should include taking a history of ear problems 
in adolescents. In particular, low resource communities providing services for PHIV+ 
adolescents without access to AC testing should use a history of ear pain or discharge in the 
last month as a means of early detection of hearing loss. Ear pain or discharge should 
function as a criterion for referral for further audiological assessment. Caregivers have not 





symptoms of pain or discharge have functioned as reliable predictors of hearing loss among 




Despite the limitations of this analysis, there is sufficient evidence that continued investigation of 
hearing loss among adolescents remains imperative, especially in populations who possess risk factors 
for hearing loss. 
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Appendix C1 Flow Diagram Showing Participant Selection for Analysis 
 
Appendix C1 is a flow diagram that illustrates the selection of participants who were 
analysed in this study. This flow diagram structure is adapted from the CONSORT 
Guidelines, despite its traditional use as a tool for randomised trial for two groups, it was 
useful as we analysed two groups (HIV-uninfected and perinatally HIV-infected). 
Appendix C2 shows the baseline characteristics of participants who were included in the 






Appendix C2 Demographic and Clinical Features of all 540 Participants  




Demographics    
Sex–no. (%) Male 273 (51) 
 Female 267 (49) 
HIV Status-np. (%) Uninfected 108 (20) 
 Perinatally infected 432 (80) 
Median age-yr. (IQR)  12.0 (10.6-13.3) 
Age Category –no. (%) <12 years 276 (51) 
 ≥12 years 264 (49) 
Median BMI- (IQR)§  17.3 (16.1-19.3) 
BMI category –no. (%) <18.5 356 (66) 
 ≥18.5 184 (34) 
Race–no. (%) Black 503 (93) 
 Coloured 37 (7) 
Socioeconomic Factors    
Primary language spoken at home–no. (%) IsiXhosa 475 (88) 
 Afrikaans/English/Sesotho/Other 65 (12) 
Current+ caregiver–no. (%) Parent 303 (56) 
 Not parent 237 (44) 
Caregiver marital status–no. (%)       Married 179 (33) 
 Divorced/Single/Other 361 (67) 
Caregiver level of education–no. (%) Below tertiary 469 (89) 
 Above Tertiary 60 (11) 
Dependence on social grant–no. (%) Yes 447 (84) 
 No 85 (16) 
Currently still in school–no. (%)++ Yes   530 (98) 
 No 10 (2) 
Medical History    
Previous diagnosis of TB–no. (%) Yes 151 (28) 
 No 389 (72) 
Experienced ear discharge or ear pain in the last one month- 
no. (%) 
Yes 87 (16) 
 No 453 (84) 
Physical Examination    
External ear examination left and right ear Both ears normal 523 (97) 
 Otitis externa/other finding in 
either or both ears 
17 (3) 
Audiometry -Pure Tone Air Conduction Testing(AC)    
Prevalence of hearing loss (PTA>30Db)– no. (%)  105 (19) 
Presence of hearing loss(PTA>30dB)– no. (%) None 435 (81) 
 Any (bilateral or unilateral) 105 (19) 
Presence of hearing loss(PTA>30dB)– no. (%) None 397 (74) 
 Unilateral 82 (15) 
 Bilateral (Better ear >30Db) 61 (11) 
Median PTA of all ears-dB (IQR)  20.4 (15.0-27.5) 
PTA by side of ear– no. (%) Right ear PTA ≤ 30 dB 444 (82) 
 Right ear PTA >30 dB 96 (18) 
 Left ear PTA ≤ 30 dB 432 (80) 
 Left ear PTA >30 dB 108 (20) 
Median PTA by side of ear -dB (IQR) Right 20.0 (13.3-27.5) 
 Left 20.0 (15.0-26.7) 
Median PTA by best and worst ear- dB (IQR) Best ear 16.7 (11.7-23.3) 
 Worst ear 23.3 (18.3-33.3) 
§1 participant missing body mass index 
 
Appendix C3 and C4 show results for the logistic regression models built for predicting 
the binary outcome for unilateral hearing loss (unilateral hearing loss not present vs 
unilateral hearing loss present) and bilateral hearing loss (bilateral hearing loss not 
present vs bilateral hearing loss present), respectively. Using STATA 13 (STATA for 





were used to assess the impact of variables that were associated (p < 0.05) with hearing 
loss (any, unilateral or bilateral). Variables included in the final, multivariate model 
were those with a p-value< 0.2 in the initial univariate analysis as shown. Confounders 





Appendix C3 Univariate and Adjusted Associations (Logistic Regression Models) Among all Participants and HIV Infected Participants for 
Binary Outcome of Unilateral Hearing Loss  
 
All Participants (HIV Infected and HIV Uninfected, n= 479) 
 Univariate Regression Model  Adjusted Regression Model 
Variable N Odds Ratio 95% Confidence Interval P Value  N Odds Ratio 95% Confidence Interval P Value 
Body Mass Index ≥18.5 479 0.97 (0.59;1.61) 0.915  - - - - 
Age   ≥12 yr. 479 0.84 (0.52;1.36) 0.480  - - - - 
Female 479 1.55 (0.96;2.51) 0.072  469 1.63 (0.99;2.69) 0.056 
Coloured 479 0.97 (0.38;2.40) 0.940  - - - - 
Not IsiXhosa speaking  479 1.10 (0.55;2.22) 0.790  - - - - 
Participants has had TB 479 1.31 (0.78;2.19) 0.308  - - - - 
Participant currently in school+ 470     -    
Primary caregiver is parent 479 0.83 (0.52;1.34) 0.456  - - - - 
Caregiver no tertiary education 469 2.21 (0.85;5.74) 0.102  469 2.19 (0.83;5.79) 0.114 
Caregiver not married 479 0.57 (0.35;0.92) 0.022  469 0.52 (0.31;0.86) 0.011 
Household has no grant  472 0.96 (0.49;1.88) 0.904  - - - - 
Troubled by ear pain/discharge 479 2.87 (1.64;5.03) <0.001  469 3.05 (1.71;5.43) <0.001 
Any otitis externa/other 479 1.47 (0.40;5.46) 0.565  - - - - 
HIV infected 479 1.44 (0.76;2.74) 0.258  - - - - 
 
Restricted to HIV Infected Participants (n=381) 
 Univariate Regression Model  Adjusted Regression Model 
Variable N Odds Ratio 95% Confidence Interval P Value  N Odds Ratio 95% Confidence Interval P Value 
% CD4≥25 381 1.18 (0.65;2.16) 0.584  - - - - 
Duration of ART ≥ 8 yr. 381 1.73 (1.02;2.92) 0.042  381 1.66 (0.98;2.82) 0.061 
CD4 Count (vs<200 cells/mm3) 381     -    
≥200 - <500 cells/mm3  1.13 (0.12;10.82) 0.912   - - - 
≥500 cells/mm3  2.44 (0.31;19.42) 0.399   - - - 
Viral load (vs ≤ 50 cells/ml) 381     381    
>50 - <1000 copies per millilitre  0.93 (0.41;2.11) 0.859   0.97 (0.42;2.20) 0.933 
≥1000 copies per millilitre  0.50 (0.19;1.31) 0.159   0.55 (0.21;1.45) 0.226 
Age at ART initiation (vs 0 -2 yr.) 373     -    
3-5 yr.  0.73 (0.37;1.44) 0.370   - - - 
6-14 yr.  0.74 (0.40;1.37) 0.343   - - - 
ART regimen (vs 2XNRTI +NNRTI) 374     -    
2xNRTI + PI  1.27 (0.74;2.19) 0.392   - - - 
Other regimen   1.26 (0.14;11.55) 0.840   - - - 








Appendix C4 Univariate and Adjusted Associations (Logistic Regression Models) Among all participants and HIV Infected Participants for 
Binary Outcome of Bilateral Hearing Loss  
 
All Participants (HIV Infected and HIV Uninfected, n= 458) 
 Univariate Regression Model  Adjusted Regression Model 
Variable N Odds Ratio 95% Confidence Interval P Value  N Odds Ratio 95% Confidence Interval P Value 
Body Mass Index ≥18.5 458 0.79 (0.44;1.41) 0.421  - - - - 
Age   ≥12 yr. 458 0.68 (0.39;1.17) 0.162  451 0.68 (0.39;1.20) 0.186 
Female 458 1.67 (0.96;2.88) 0.067  451 1.61 (0.92;2.82) 0.098 
Coloured 458 0.20 (0.03;1.52) 0.121  451 0.21 (0.03;1.57) 0.128 
Not IsiXhosa speaking  458 0.63 (0.24;1.66) 0.354  - - - - 
Participants has had TB 458 1.48 (0.83;2.62) 0.181  451 1.21 (0.65;2.24) 0.547 
Participant currently in school 458 1.39 (0.17;11.18) 0.756  - - - - 
Primary caregiver is parent 458 0.95 (0.55;1.64) 0.861  - - - - 
Caregiver no tertiary education 449 1.62 (0.62;4.25) 0.324  - - - - 
Caregiver not married 458 0.85 (0.48;1.49) 0.562  - - - - 
Household has no grant  451 1.52 (0.78;2.99) 0.218  451 1.56 (0.78;3.13) 0.208 
Troubled by ear pain/discharge 458 1.88 (0.95;3.71) 0.069  451 1.85 (0.91;3.72) 0.087 
Any otitis externa/other 458 2.72 (0.82;8.95) 0.101  451 2.78 (0.80;9.59) 0.106 
HIV infected 458 1.39 (0.68;2.85) 0.370  451 1.58 (0.71;3.53) 0.266 
 
Restricted to HIV Infected Participants (n=363) 
 Univariate Regression Model  Adjusted Regression Model 
Variable N Odds Ratio 95% Confidence Interval P Value  N Odds Ratio 95% Confidence Interval P Value 
% CD4≥25 363 1.41 (0.69;2.86) 0.348  - - - - 
Duration of ART ≥ 8 yr. 363 1.90 (1.04;3.46) 0.037  356 1.15 (0.48;2.74) 0.749 
CD4 Count (vs<200 cells/mm3) 363     -    
≥200 - <500 cells/mm3  1.36 (0.15;12.6) 0.785   - - - 
≥500 cells/mm3  1.71 (0.19;13.7) 0.615   - - - 
Viral load (vs ≤ 50 cells/ml) 363     -    
>50 - <1000 copies per millilitre  0.49 (0.14;1.66) 0.250   - - - 
≥1000 copies per millilitre  1.11 (0.49;2.55) 0.798   - - - 
Age at ART initiation (vs 0 -2 yr.) 356     356    
3-5 yr.  0.64 (0.31;1.32) 0.225   0.81 (0.35;1.86) 0.615 
6-14 yr.  0.38 (0.18;0.81) 0.012   0.55 (0.18;1.66) 0.287 
ART regimen (vs 2XNRTI +NNRTI) 357     356    
2xNRTI + PI  1.76 (0.95;3.26) 0.075   1.44 (0.74;2.80) 0.285 
Other regimen   6.13 (1.29;29.03) 0.022   4.08 (0.80;20.71) 0.090 






Appendix C5 Letter of Study Approval 
Appendix C5 shows the ethics approval letter issued by the Faculty of Health Sciences Human 





Appendix C7 shows Tropical Medicine & International Health author guidelines for 
submitting articles. The manuscript should is duly accompanied by Appendix C6.  
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